WO2015080319A1 - Cholesterol derivative-based liquid crystal and liquid crystal capsules containing same - Google Patents
Cholesterol derivative-based liquid crystal and liquid crystal capsules containing same Download PDFInfo
- Publication number
- WO2015080319A1 WO2015080319A1 PCT/KR2013/010999 KR2013010999W WO2015080319A1 WO 2015080319 A1 WO2015080319 A1 WO 2015080319A1 KR 2013010999 W KR2013010999 W KR 2013010999W WO 2015080319 A1 WO2015080319 A1 WO 2015080319A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cholesteryl
- liquid crystal
- liquid
- ester
- halide
- Prior art date
Links
- 239000004973 liquid crystal related substance Substances 0.000 title claims abstract description 109
- 239000002775 capsule Substances 0.000 title claims abstract description 61
- 150000001841 cholesterols Chemical class 0.000 title claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 55
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 239000011257 shell material Substances 0.000 claims abstract description 23
- 238000010438 heat treatment Methods 0.000 claims abstract description 21
- 238000001816 cooling Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 5
- -1 cholesteryl halide Chemical class 0.000 claims description 98
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 26
- 239000002537 cosmetic Substances 0.000 claims description 16
- 239000004615 ingredient Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- OTVRYZXVVMZHHW-FNOPAARDSA-N (8s,9s,10r,13r,14s,17r)-3-chloro-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical group C1C=C2CC(Cl)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OTVRYZXVVMZHHW-FNOPAARDSA-N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 230000008591 skin barrier function Effects 0.000 claims description 6
- HOMYIYLRRDTKAA-UHFFFAOYSA-N 2-hydroxy-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]hexadecanamide Chemical compound CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=CCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O HOMYIYLRRDTKAA-UHFFFAOYSA-N 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- WCLNGBQPTVENHV-MKQVXYPISA-N cholesteryl nonanoate Chemical group C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCC)C1 WCLNGBQPTVENHV-MKQVXYPISA-N 0.000 claims description 5
- 239000006166 lysate Substances 0.000 claims description 3
- 239000000155 melt Substances 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 230000003752 improving hair Effects 0.000 claims description 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 2
- 230000009759 skin aging Effects 0.000 claims description 2
- 230000037394 skin elasticity Effects 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 claims 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical group C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 claims 1
- 125000002210 galactosylceramide group Chemical group 0.000 claims 1
- 238000004898 kneading Methods 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000009472 formulation Methods 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 13
- 229930182830 galactose Natural products 0.000 description 11
- 125000003147 glycosyl group Chemical group 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 229940106189 ceramide Drugs 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- JBBRZDLNVILTDL-XNTGVSEISA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 16-methylheptadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC(C)C)C1 JBBRZDLNVILTDL-XNTGVSEISA-N 0.000 description 6
- 229940073724 cholesteryl isostearate Drugs 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229920002148 Gellan gum Polymers 0.000 description 5
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 235000010492 gellan gum Nutrition 0.000 description 5
- 239000000216 gellan gum Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- ZETHHMPKDUSZQQ-UHFFFAOYSA-N Betulafolienepentol Natural products C1C=C(C)CCC(C(C)CCC=C(C)C)C2C(OC)OC(OC)C2=C1 ZETHHMPKDUSZQQ-UHFFFAOYSA-N 0.000 description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 4
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 4
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 206010056474 Erythrosis Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 4
- HEOKFDGOFROELJ-UHFFFAOYSA-N diacetal Natural products COc1ccc(C=C/c2cc(O)cc(OC3OC(COC(=O)c4cc(O)c(O)c(O)c4)C(O)C(O)C3O)c2)cc1O HEOKFDGOFROELJ-UHFFFAOYSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 150000002254 galactosylceramides Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- MHSRBJIRDADQGQ-UHFFFAOYSA-N 4-chloro-2-methyl-5-phenylthieno[2,3-d]pyrimidine Chemical compound C=1SC2=NC(C)=NC(Cl)=C2C=1C1=CC=CC=C1 MHSRBJIRDADQGQ-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229940044176 ceramide 3 Drugs 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 150000002772 monosaccharides Chemical group 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 2
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000010029 Homer Scaffolding Proteins Human genes 0.000 description 2
- 108010077223 Homer Scaffolding Proteins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- NAACPBBQTFFYQB-UHFFFAOYSA-N Linolsaeure-cholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCC=CCCCCC)C2 NAACPBBQTFFYQB-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- NAACPBBQTFFYQB-XNTGVSEISA-N cholesteryl octadeca-9,12-dienoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCC=CCC=CCCCCC)C1 NAACPBBQTFFYQB-XNTGVSEISA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000002402 hexoses Chemical group 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WDRGNJZPWVRVSN-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-3-bromo-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1C=C2C[C@@H](Br)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WDRGNJZPWVRVSN-DPAQBDIFSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- CKDZWMVGDHGMFR-UHFFFAOYSA-N Buttersaeure-cholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCC)C2 CKDZWMVGDHGMFR-UHFFFAOYSA-N 0.000 description 1
- GIPFSGBUGVMIOA-BMRADRMJSA-N CCCCCCCCCCCCCCC(C(C(COC(C(C1O)O)OC(CO)C1O)NC(CCCCCCCC/C=C/CCCCCCC)=O)O)O Chemical compound CCCCCCCCCCCCCCC(C(C(COC(C(C1O)O)OC(CO)C1O)NC(CCCCCCCC/C=C/CCCCCCC)=O)O)O GIPFSGBUGVMIOA-BMRADRMJSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- RMLFYKFCGMSLTB-ZBDFTZOCSA-N Cholesteryl laurate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC)C1 RMLFYKFCGMSLTB-ZBDFTZOCSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- BBJQPKLGPMQWBU-UHFFFAOYSA-N Palmitinsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCC)C2 BBJQPKLGPMQWBU-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- CKDZWMVGDHGMFR-GTPODGLVSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] butanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCC)C1 CKDZWMVGDHGMFR-GTPODGLVSA-N 0.000 description 1
- XMPIMLRYNVGZIA-CCEZHUSRSA-N [10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] [(e)-octadec-9-enyl] carbonate Chemical compound C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)OCCCCCCCC/C=C/CCCCCCCC)C2 XMPIMLRYNVGZIA-CCEZHUSRSA-N 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- BBJQPKLGPMQWBU-JADYGXMDSA-N cholesteryl palmitate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC)C1 BBJQPKLGPMQWBU-JADYGXMDSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- VTRGQZOKQCSGAD-UHFFFAOYSA-M decyl carbonate Chemical compound CCCCCCCCCCOC([O-])=O VTRGQZOKQCSGAD-UHFFFAOYSA-M 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 150000003019 phosphosphingolipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 150000004609 retinol derivatives Chemical class 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Definitions
- a liquid crystal including a cholester derivative, a capsule in which the liquid crystal is collected, a method of preparing the capsule, and a composition including the capsule are provided.
- liquid crystal Most organic crystalline solids have a specific transmittance according to the melting temperature of the solid. This represents a unique color range for heating solids. This phenomenon is called liquid crystal. Most of the liquid crystals are found in the form of ester-bonded cholesterol compounds, and most forms of light have the effect of inverting colors. This phenomenon is caused by light scattering due to changes in the physical structure with temperature. However, the problem of cholesterol-based liquid crystals is that they become solid due to the change in viscosity with temperature, and in addition, the viscous liquid crystals have many problems to deal with. In particular, in the development of cosmetic materials, the color tends to disappear depending on the raw materials used, which is not available in most formulations, and is used only in cosmetics using specific materials.
- an object of the present invention is to provide a stable liquid crystal.
- an object of the present invention is to provide a liquid crystal suitable as an external skin material.
- the present invention provides a carrier capable of stably carrying components useful for the skin.
- the liquid crystal capsule according to the present invention comprises a core and a shell for collecting the core, wherein the core is a liquid crystal containing a cholester derivative. It includes a mask.
- the method for producing a liquid crystal capsule according to the present invention comprises the steps of heating and cooling the cholesterol derivative to obtain a liquid crystal; Heating the liquid crystal, and then adding a shell material, or a shell material and a useful ingredient together and then mixing to obtain a slime liquid; And cooling the mucus liquid through a jet having a micro diameter.
- the composition according to the invention comprises a core and a shell for capturing the core, the core comprising a liquid crystal ramsule comprising a cholesterol derivative.
- liquid crystal disclosed in this specification and the liquid crystal containing the same, the liquid crystal of the form suitable for use for cosmetics, a cosmetics for external skin, etc. can be provided. This can be applied to various formulations of cosmetics.
- the liquid crystals disclosed herein and capsules containing the same can be usefully used in functional cosmetic products or pharmaceutical compositions because they can stably maintain and deliver useful ingredients. .
- FIG. 1 is a photograph of a liquid crystal capsule prepared according to an embodiment of the present disclosure.
- FIG. 2 is a schematic diagram of a capsul preparation method disclosed herein.
- FIG. 3 is a photograph of a liquid crystal decapsulating capsule containing a useful ingredient prepared according to an embodiment of the present specification.
- Figure 4 is a sand showing the regeneration effect of the damaged skin epidermal layer
- Figure 4 (a) is a skin in which the lipid layer is missing in the epidermal layer
- Figure 4 (b) is a control
- Figure 4 (c) is a liquid crystal de The picture is shown after the capsules have been treated.
- FIG. 5 is a graph showing the water evaporation rate (TEWL) for 1 day after applying the liquid crystallized using a cholesterol derivative and galactosyl ceramide to the damaged skin.
- the liquid crystal capsule according to the present invention comprises a core and a shell for capturing the core, wherein the core comprises a liquid crystal containing a cholesterol derivative.
- the method for producing a liquid crystal capsule according to the present invention comprises the steps of obtaining a liquid crystal by cooling the cholester derivative after heating; Heating the liquid crystal and then adding a shell material, or a shell material and a useful ingredient together and then mixing to obtain a slime liquid; And cooling the slime liquid through a jet having a micro diameter.
- the composition according to the invention comprises a core and a shell for collecting the core, the core comprising a liquid crystal comprising a cholester derivative.
- the cholesterol derivative may comprise one or more of cholesteryl halides and cholesteryl esters.
- the cholesteryl halide may be at least one selected from the group consisting of cholesteryl chloride, cholesteryl bromide, cholesteryl iodo and cholesteryl nitrate.
- the cholesteryl ester may be an ester of unsaturated fatty acid or saturated fatty acid percholester having from d to c 22 carbon atoms.
- the liquid crystal may include a combination of cholesteryl halides and cholesteryl esters, and the liquid crystals may have one or more colors of green, red, and blue.
- the cholester ester may include cholester ester in a liquid state.
- the cholesteryl halide is cholesteryl chloride
- the cholesteryl ester may be a liquid crystal capsule of cholesteryl nonaate and cholesteryl isostearate.
- the cholesteryl ester may include a non-liquid cholesteryl ester and a liquid cholesteryl ester.
- Liquid cholesteryl esters can be used with any cholesteryl ester as long as they are liquid at room temperature.
- cholesteryl acrylate and cholesteryl isostearlay can be used with any cholesteryl ester as long as they are liquid at room temperature.
- Non-liquid cholesteryl esters may be any cholesteryl ester as long as they are non-liquid at room temperature, such as cholesteryl nonaate cholesteraryl acetate, cholesteryl palmitate or one or more of the above. Or a combination of esters.
- the amount of cholesteryl halide is 5 to 5 based on the total liquid crystal weight.
- the amount of cholesteryl halide can be 20 to 40 weight percent based on total liquidcris descaling. In one aspect, the amount of cholesteryl halide may be at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 or 65% by weight based on the total liquid crystal weight. In another aspect, the amount of cholesteryl halide can be up to 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15 or 10 weight percent based on the total liquid crystal weight.
- the amount of cholesteryl ester can be 25 to 95 weight percent based on the total liquid crystal weight. In one aspect the amount of cholesteryl ester can be from 60 to 80% by weight based on the total amount of liquid crystals. In one axis, the amount of cholesteryl ester is 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, based on the total amount of liquid crystals. 90 or 95% by weight or more. In another aspect, the amount of cholesteryl ester can be up to 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15 or 10 weight percent based on the total liquid crystal weight.
- the amount of the liquid cholesteryl ester may be 50 to 300 parts by weight based on 100 parts by weight of the non-liquid cholesteryl ester. On one side ' .
- the amount of the liquid cholesteryl ester may be 70 to 200 parts by weight based on 100 parts by weight of the non-liquid cholesteryl ester.
- the amount of liquid cholesteryl ester is 50, 60, 70, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260 based on 100 parts by weight of the non-liquid cholesteryl ester. Or 280 parts by weight or more.
- the amount of liquid phosphorus cholesteryl ester is increased by 260, 240, 220, 200, 180, 160, 140, 120, 100, 80, 60 or 50 based on 100 parts by weight of the non-liquid cholesteryl ester. Or less.
- the color of the liquid crystal is green
- the weight ratio of cholesteryl halide: non-liquid cholesteryl ester: liquid cholesteryl ester can be 25-35: 55-65: 45-55. have.
- the color of liquid crystal is red
- cholesteryl halide Liquid cholesteryl ester: The weight ratio of liquid cholesteryl ester may be 45-55: 25-50: 45-55.
- the color of the liquid crystal is blue
- the cholesteryl halide : non-liquid cholesteryl ester the weight ratio of the liquid cholesteryl ester can be 35-45 : 45-55 : 45-55 days have.
- the cholesteryl halide is cholesteryl chloride
- the non-liquid cholesteryl ester is cholesteryl nonanoate
- the liquid cholesteryl ester is cholesteryl stearateyl.
- capsule refers to a structure comprising one or more solid or liquid cores surrounded by one or more continuous shells.
- Natural shell materials include, for example, gum arabic, agar, agarose, maltodextrin, alginic acid and salts thereof, such as sodium or calcium alginate, fats and fatty acids, cetyl alcohol, collagen, chitosan, lecithin, gelatin, Such as gellan gum, collagen, and chondroitin sulfate
- Semi-synthetic shell materials include, in particular, chemically modified cellulose, more particularly cellulose esters and cellulose ethers, for example cellulose acetate, ethyl salose, hydroxypropyl cellulose, hydroxypropyl Methyl cellulose and carboxymethyl cellulose, and starch derivatives, more particularly starch ethers and starch esters.
- Synthetic shell materials include, for example, polymers such as polyacrylate, polyamide, polyvinyl alcohol or polyvinylpyridone.
- the shell may be agar, gellan gum, wax or any combination thereof.
- the shell may be present in an amount of 0.1 to 30% by weight based on the total weight of the capsule. In one aspect, the shell may be present in an amount of 0.5 to 10 weight 3 ⁇ 4 based on the total weight of the capsule.
- the method for producing a liquid crystal capsule according to the present invention comprises the steps of obtaining a liquid crystal by cooling the cholester derivatives after heating; Heating the liquid crystal and then adding the shell material, or the 3 ⁇ 4 material and the useful component together and then mixing to obtain a slime liquid; And cooling the slime liquid through a jet having a micro diameter.
- the liquid crystal comprises heating the cholesteryl halide; remind Adding cholesteryl ester to the heated cholesteryl halide to dissolve it; And it may be prepared by a method comprising the step of cooling the lysate.
- the liquid crystal comprises heating the cholesteryl halide; Dissolving and adding non-liquid cholesteryl ester to the heated cholesteryl halide; Adding liquid cholesteryl ester to the melt; And it may be prepared by a method comprising the step of entangling the lysate.
- the step of passing the mucus liquid through a jet having a micro diameter and then engraving the drop is added dropwise to the water or oil previously cooled.
- Can include In one aspect, it is possible to filter the spherical bodies obtained through the dropping through the mesh.
- the heating temperature of the cholesteryl derivative may be 40 to 80 ° C. In another aspect, the heating temperature of the cholesteryl derivative may be 80, 75, 70, 65, 60, 55, 50, or 45 fc or less. In another aspect, the heating temperature of the cholesteryl derivative may be at least 40, 45, 50, 55, 60, 65, or 70 ° C.
- the cooling temperature of the cholesteryl derivative may be a temperature of 5 to 30 ° C. In one aspect, the cooling temperature of the cholesteryl derivative may be room temperature.
- the cholesteryl halide is heated to a temperature from 40 to 80 ° C in an amount of 5 to 40 weight 3 ⁇ 4 based on the total liquid crystal increase, and then the cholesteryl ester is added to 5 to 40 weight 3 ⁇ 4.
- cholesteryl acrylate, cholesteryl isostearate, and cholesteryl which are liquid components of cholesteryl ester
- Liquid crystals can be prepared by adding oleylcarbonate, cholesteryl isostearylcarbonate or a combination of one or more of these esters up to 20 to 40 weight 3 ⁇ 4.
- the heating temperature of the liquid crystal may be 60 to 100 ° C. In another aspect, the heating temperature of the liquid crystal may be 100, 95, 90, 85, 80, 75, 70, or 65 ° C or less. In another aspect, the heating temperature of the liquid crystal may be at least 60, 65, 70, 75, 80, 85, 90 or 95 ° C.
- the cooling temperature of the liquid crystal may be a temperature of 1 to 30 ° C.
- the content of the shell material such as agar, gellan gum, wax, etc. in order to encapsulate liquid crystalol, from 0.5 to 10 weight 3 ⁇ 4 based on the total weight of the capsule, is added dropwise to water or oil, Transparent spheres can be obtained.
- Transparent spheres can be obtained.
- galactosyl The content of useful skin ingredients such as ceramides, ceramides, lecithin, tocophenols and polyphenols can be dissolved from 0.1 to 10% by weight based on the total weight of the capsule and added before the capsules are formed to make capsules containing the substance. .
- the core may further comprise a useful ingredient.
- the useful ingredient may be a fat-soluble useful ingredient.
- glycosyl ceramides such as ceramides, galactosyl ceramides, retinol, retinol derivatives, retinyl acetate, retinyl palmitate, tocofe, tocopheryl acetate, tocopheryl linate, tocopheryl nicotinate, epi Gallocatechin gallate, alpha lipoic acid, linoleic acid, coenzyme Q-10, lezberat, hyaluronic acid, plant extract essential oils and derivatives thereof, or combinations thereof.
- the useful ingredient may be galactosyl ceramide.
- glycosyl ' ceramide may be a glycosyl ceramide compound represented by the following formula (1).
- N is an integer of 1 to 4
- M is an integer of 1 to 4,
- R 1, R 2 and 3 ⁇ 4 each independently represent hydrogen or the same or different
- R 4 and 3 ⁇ 4 are alkyl or alkenes having 1 to 20 carbon atoms.
- Glycosyl ceramide according to another embodiment of the present invention may be represented by Formula 1-1 or Glycosyl Ceram 0 of Formula 1-2
- the glyco ceramide according to an embodiment of the present invention may be a glycosyl ceramide compound represented by the following formula (2)
- M and n are each independently the same or different from each other 1 to 3 integers ego
- K and 1 are each independently the same or different integer increments of 1 and 2 0 j is 0 or 1,
- A is hydrogen
- a 1 and A 3 are each independently the same or different glycosyl groups, and R is an alkyl group having 1 to 30 carbon atoms.
- Glycosyl ceramide may be represented by the following formula (2-1) or (2-2). At this time, the glycosyl groups corresponding to A 1 and A 3 in Formula 1 are all galactose.
- glycosyl ceramide is a compound represented by the following formula (3) Can be.
- N is an integer of 1 to 4
- Ri, R 2 and R 3 are each independently hydrogen or the same or different glycosyl groups.
- 3 ⁇ 4 and 3 ⁇ 4 are alkyl groups or alkenes having 1 to 20 carbon atoms.
- the compound may be represented by the following Chemical Formulas 3-1 and 3-2.
- the glycosyl group is not particularly limited as long as it is a monosaccharide, but it is not particularly limited as long as it is a monosaccharide.
- galactose, ribose, arabinose, xylose, ribulose, glucose, fructose, mannose, glyceraldehyde, dihydroxyacetone, erythrose and erythrose more preferably galactose Can be.
- the galactose, ribose, arabinose, xylose, ribulose, glucose, fructose, mannose, glyceraldehyde, dihydric acetone, erythrose, erythrose are monosaccharides represented by the following formulas, respectively, in order.
- the glycosyl group may be sugar. In another embodiment, the glycosyl group may be galactose.
- the glycosyl group may be combined with ceramide at the carbon position of hexose.
- the carbon position of hexose 1 is, for example, galactose:
- the useful ingredient may comprise 0.001 to 80% by weight relative to the total capsule weight. In one aspect, the useful ingredient may comprise 0.1, 1, 2, 4, 5, 7, 8, 9, 10, 15, 20, 30, 40 or 50% by weight or more based on the total capsule weight. In one aspect, the useful ingredient may contain up to 70, 60, 50, 40, 30, 20 or 10% by weight relative to the total capsule weight,
- the composition according to the present invention is intended to improve the skin barrier function, improve skin elasticity, repair damaged skin, moisturize skin, improve wrinkles, prevent skin aging, improve hair condition, or treat or alleviate atopic skin It may be a composition having.
- the composition according to the present invention may be an external preparation for skin.
- the composition according to the present invention may be a cosmetic composition or a pharmaceutical composition.
- the pharmaceutical composition may be a composition for transdermal administration.
- Any pharmaceutically acceptable carrier included in the pharmaceutical composition of the present invention may be used as long as it is commonly used at the time of presentation.
- lactose dextrose, sucrose, solbi, manny, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, Syrup, methyl cellulose, methyl hydroxybenzoate,
- the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavor, an emulsifier, a suspending agent, a preservative, and the like, in addition to the above components.
- compositions of the present invention can be administered in a variety of ways, Leisure is most preferred. In particular, it is applied by applying to the skin locally.
- Appropriate dosages of the pharmaceutical compositions of the present invention may include factors such as formulation method, mode of administration, age of patient, degree of disease, degree of disease symptom, food, time of administration, route of administration, rate of excretion and response.
- the skilled practitioner can readily determine and prescribe a dosage that is effective for the desired treatment.
- the daily dose of the pharmaceutical composition of the present invention is about 0.001-100 rag / kg.
- the pharmaceutical composition of the present invention may be formulated using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by one of ordinary skill in the art. It may be prepared in the form or prepared by incorporation into a multi-dose container. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of extracts, powders, granules, tablets or capsules, and may further include a dispersant or stabilizer. According to another aspect of the present invention, the present invention provides a functional cosmetic composition.
- the content of the liquid crystal capsule as an active ingredient in the cosmetic composition of the present invention may be 0.0001-80.0% by weight based on the total cosmetic composition. Preferably it is 0.0005-40.0 weight%, More preferably, it is 0.01-20% weight%. Even more preferably from 0.1 to 10% by weight. If the content is too low, the effect is insignificant, and if too high, the formulation stability is not good.
- Ingredients included in the cosmetic composition of the present invention include components commonly used in cosmetic compositions in addition to liquid crystal capsule as an active ingredient, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings. Conventional adjuvants such as, and carriers.
- the cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactants. —Contains, but is not limited to, cleanliness, oils, powder foundations, emulsion foundations, wax foundations, and sprays. More specifically, it may be prepared in the form of a flexible lotion, a nourishing lotion, a nourishing cream, a massage cream and a essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
- the carrier components include animal oils, vegetable oils, waxes, paraffins, starches, tracants, cellulose derivatives and polyethylene. Glycol, silicon, bentonite, silica, talc or zinc oxide may be used.
- the formulation of the present invention is a powder or a spray
- lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, and in particular, in the case of a spray, additionally chlorofluorohydrocarca. It may include a propellant such as propane / butane or dimethyl ether.
- a solvent, a solubilizer or an emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene.
- the carrier components include water, ethane or liquefied diluents such as propylene glycol, isosylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters; Suspending agents, microcrystalline cellulose, aluminum metahydride, bentonite, agar or tracant and the like can be used.
- the formulation of the present invention is a surfactant-containing cleansing agent
- Amide ether sulfates, alkylamidobetaine aliphatic alcohols, fatty acid glycerides, fatty acid diethanamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
- Example 1 Preparation of Liquid Crystal 30 g of cholesteryl chloride was added to a flask and heated to 60 ° C. for melting. Then, 60 g of cholesteryl nonanoate and 50 g of cholesteryl isostearate were added together. It melt
- ⁇ i2i> 50 g of cholesteryl chloride is added to the flask and heated to 60 ° C to dissolve.
- 30 g of cholesteryl nonanoate and 50 g of cholesteryl isostearate are dissolved together and supercooled with ice to room temperature. Obtain 130 g of Red Crystal.
- cholesteryl chloride 40 g of cholesteryl chloride is added to a flask and heated to 60 ° C to dissolve it. Then, 50 g of cholesteryl nonanoei H and 50 g of cholesteryl isostearate are dissolved together. Then, 140 g of blue liquid crystals were obtained.
- Example 2 20 g of the green liquid crystal detalized in Example 1 was added to a stirrer and heated to 80 ° C. to dissolve. 2 g of gellan gum was added to the mixture and stirred well. Then, 70 g of purified water and 6 g of galactosyl ceramide prepared in Example 3 were added to the mixture, followed by stirring. The mixture was stirred at 200 rpm for 5 minutes using a homer mixer. The viscous liquid thus obtained was slowly added dropwise to another stirrer containing fire cooled by KC through a spout of average size 5 to 30 microns. The spheres thus obtained were filtered through a 30 mesh network to obtain a capsule containing liquid crystals.
- the size of the capsule obtained at this time is 5 to 10 mils in diameter.
- the concentration of galactosyl ceramide in the liquid crystal capsule was about 3% by weight.
- the prepared liquid crystal capsule containing galactosyl ceramide is shown in FIG. 3.
- FIG. Figure 4 (a) lipids in the epidermal layer The layer is missing skin
- Figure 4 (b) is a control
- Figure 4 (c) shows a photograph after treatment with liquid crystal capsules.
- Example 4 After measuring with TEWLAMETER (TEWAMETER JM210, Germany) (normal skin about 10 ⁇ 2g / hm 2 ), attaching and detaching Scotch tape on one upper lip 20 times, and the amount of moisture in water is 40-50g / hm 2 Repeat until this time. Next, the liquid crystal capsules of Example 4 were coated with 20ul immediately after the damage, 45 minutes later, 6 hours later, 12 hours later, and 24 hours later. As the time elapsed, the water evaporation was measured 6 hours, 12 hours and 24 hours immediately after each damage.
- TEWLAMETER TEWAMETER JM210, Germany
- the result is the recovery of the TEWL of the subject skin from the normal TEWL before the injury, and is expressed as a relative value when the TEWL recovery rate after the injury is 0% and the normal TEWL before the injury is 100%.
- the results are shown in FIG. As shown in Figure 5, it can be seen that the treatment of the liquid crystal capsule containing galactosyl ceramide has a high skin barrier restoration effect.
- liquid crystal capsule containing galactosyl ceramide and the composition containing the same were prepared according to a conventional method in the following composition ratio, but the present invention is not limited only to the following examples.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
The present specification discloses liquid crystal capsules comprising a core and a shell which captures the core, wherein the core comprises cholesterol derivatives. In addition, disclosed is a method for producing liquid crystal capsules, the method comprising steps of: heating the cholesterol derivatives and then cooling the same to obtain liquid crystal; heating the liquid crystal, followed by adding shell materials or shell materials with added useful components, and then mixing the same to obtain viscous liquid; and allowing the viscous liquid to pass through a vent with a micro diameter, and then cooling the same. Also, a composition comprising liquid crystal capsules is provided, the capsules comprising a core and a shell which captures the core, and the core comprising cholesterol derivatives.
Description
【명세서】 【Specification】
【발명의 명칭】 [Name of invention]
콜레스테를 유도체 기반의 리퀴드크리스탈 및 이를 함유한 리퀴드크리스탈 캡슐 Liquid crystals based on cholester derivatives and liquid crystal capsules containing them
【기술분야】 Technical Field
<ι> 본 명세서에는 콜레스테를 유도체를 포함하는 리퀴드크리스탈, 상기 리퀴드 크리스탈을 내부에 포집한 캡슐, 상기 캡슐의 제조방법, 상기 캡슐을 포함하는 조 성물이 제공된다. In the present specification, a liquid crystal including a cholester derivative, a capsule in which the liquid crystal is collected, a method of preparing the capsule, and a composition including the capsule are provided.
【배경기술】 Background Art
<2> 대부분의 유기 결정형 고체들은 고체가녹는 온도에 따른 특유의 투과율이 있다. 이는 고체를 가열 증 특유의 색깔 범위를 나타낸다. 이러한 현상을 리퀴드 크리스탈이라부른다. 리퀴드크리스탈의 대부분은 콜레스테롤에 에스테르결합을 한 형태의 화합물에서 발견되고 있으며 일정한 빛의 형태들은 대부분 색의 반전되 는 효과가 있다. 이러한 현상은 온도에 따라물리적인 구조의 변화로 인한 빛의 산 란에 의해 발생한다. 그러나콜레스테롤 베이스 리퀴드 크리스탈의 문제점은 온도 에 따라 점성이 변함으로 인해서 고체화 되는 것이며, 그 외에도 점액성의 리퀴드 크리스탈은 다루기에도 문제점이 많다. 특히, 화장품 소재로의 개발에 있어 사용하 는 원료에 따라 색이 없어 지는 경향이 뚜렷하여 대부분의 제형에서는사용이 불가 하며, 특정 소재를 이용한화장품에서만사용이 되고 있는 실정이다. Most organic crystalline solids have a specific transmittance according to the melting temperature of the solid. This represents a unique color range for heating solids. This phenomenon is called liquid crystal. Most of the liquid crystals are found in the form of ester-bonded cholesterol compounds, and most forms of light have the effect of inverting colors. This phenomenon is caused by light scattering due to changes in the physical structure with temperature. However, the problem of cholesterol-based liquid crystals is that they become solid due to the change in viscosity with temperature, and in addition, the viscous liquid crystals have many problems to deal with. In particular, in the development of cosmetic materials, the color tends to disappear depending on the raw materials used, which is not available in most formulations, and is used only in cosmetics using specific materials.
<3> <3>
【발명의 상세한설명】 Detailed Description of the Invention
【기술적 과제】 [Technical problem]
<4> 일 측면에서, 본 발명의 목적은 안정한 리퀴드크리스탈을 제공하는 것이다. In one aspect, an object of the present invention is to provide a stable liquid crystal.
<5> 일 측면에서, 본 발명의 목적은 피부 외용 재료로서 적합한 리퀴드크리스탈 을 제공하는 것이다. In one aspect, an object of the present invention is to provide a liquid crystal suitable as an external skin material.
<6> 일 측면에서, 본 발명의 목적은 화장품 또는 피부 외용 의약품으로서 적합한 리퀴드크리스탈을 제공하는 것이다. In one aspect, it is an object of the present invention to provide a liquid crystal suitable as a cosmetic or cosmetic product for external skin.
<7> 일 측면에서, 본 발명은 피부에 유용한 성분들을 안정하게 운반할 수 있는 담체를 제공하는 것이다. In one aspect, the present invention provides a carrier capable of stably carrying components useful for the skin.
【기술적 해결방법】 Technical Solution
<8> 일 측면에서, 본 발명에 따른 리퀴드크리스탈 캡술은, 코어 및 상기 코어를 포집하는 쉘을 포함하며, 상기 코어는 콜레스테를 유도체를 포함하는 리퀴드크리스
탈을포함한다. In one aspect, the liquid crystal capsule according to the present invention comprises a core and a shell for collecting the core, wherein the core is a liquid crystal containing a cholester derivative. It includes a mask.
<9> 일측면에서, 본 발명에 따른 리퀴드크리스탈 캡슐의 제조방법은, 콜레스테롤 유도체를 가열한후 냉각시켜 리퀴드크리스탈을 얻는 단계; 상기 리퀴드크리스탈을 가열한후 쉘 재료, 또는 쉘 재료와유용성분을 함께 첨가한 다음 흔합하여 점액성 액체를 얻는 단계; 및 상기 점액성 액체를 마이크로 직경을 갖는분출구를 통과시 킨 후 냉각시키는 단계를포함한다. In one aspect, the method for producing a liquid crystal capsule according to the present invention comprises the steps of heating and cooling the cholesterol derivative to obtain a liquid crystal; Heating the liquid crystal, and then adding a shell material, or a shell material and a useful ingredient together and then mixing to obtain a slime liquid; And cooling the mucus liquid through a jet having a micro diameter.
<10> 일측면에서, 본 발명에 따른 조성물은 코어 및 상기 코어를 포집하는 쉘을 포함하며, 상기 코어는 콜레스테롤 유도체를 포함하는 리퀴드크리스탈 램슐을 포함 한다. In one aspect, the composition according to the invention comprises a core and a shell for capturing the core, the core comprising a liquid crystal ramsule comprising a cholesterol derivative.
【유리한 효과] Advantageous Effects
<11> 본 명세서에 개시된 리퀴드크리스탈 및 그를 함유한 캡슬^ 화장품이나 피부 외용 의약품 등에 사용하기에 적합한 형태의 리퀴드크리스탈을 제공할 수 있다. 이 를 통해 화장품의 다양한 제형에 응용할 수 있다. 또한 본 명세서에 개시된 리퀴 드크리스탈 및 그를 함유한 캡슐은 유용 성분들을 안정하게 유지 및 전달할 수 있 으므로, 기능성 화장료 제품또는 약제학적 조성물에 유용하게 활용될 수 있다. . <11> The liquid crystal disclosed in this specification, and the liquid crystal containing the same, the liquid crystal of the form suitable for use for cosmetics, a cosmetics for external skin, etc. can be provided. This can be applied to various formulations of cosmetics. In addition, the liquid crystals disclosed herein and capsules containing the same can be usefully used in functional cosmetic products or pharmaceutical compositions because they can stably maintain and deliver useful ingredients. .
<12> - 【도면의 간단한 설명】 <12>-[short description of drawings]
<13> 도 1은 본 명세서의 실시예에 따라 제조된 리퀴드크리스탈 캡슐의 사진이다. 1 is a photograph of a liquid crystal capsule prepared according to an embodiment of the present disclosure.
<14> 도 2는 본 명세서에 개시된 캡술 제조방법의 모식도이다. FIG. 2 is a schematic diagram of a capsul preparation method disclosed herein. FIG.
<15> 도 3은 본 명세서의 실시예에 따라 제조된, 유용성분이 함유된 리퀴드크리스 탈 캡슐의 사진이다. 3 is a photograph of a liquid crystal decapsulating capsule containing a useful ingredient prepared according to an embodiment of the present specification.
<16> 도 4는 손상된 피부 표피층의 재생 효과를 나타내는 사질으로서, 도 4 (a)는 표피층에 지질층이 소실된 피부를, 도 4 ( b )는 대조군을, 도 4 ( c )는 리퀴드크리스 탈 캡슐을 처치한후 사진을 나타낸다. 4 is a sand showing the regeneration effect of the damaged skin epidermal layer, Figure 4 (a) is a skin in which the lipid layer is missing in the epidermal layer, Figure 4 (b) is a control, Figure 4 (c) is a liquid crystal de The picture is shown after the capsules have been treated.
<17> 도 5는 콜레스테롤 유도체를 이용한 리퀴드크리스탈 및 갈락토실세라마이드 를 첨가하여 ¾슐화한 소재를 손상된 피부에 도포한 후 1일 동안 수분증발율 (TEWL)을 나타낸 그래프이다. FIG. 5 is a graph showing the water evaporation rate (TEWL) for 1 day after applying the liquid crystallized using a cholesterol derivative and galactosyl ceramide to the damaged skin.
<18> <18>
【발명의 실시를 위한 최선의 형태】 [Best form for implementation of the invention]
<19> 일 측면에서, 본 발명에 따른 리퀴드크리스탈 캡슐은, 코어 및 상기 코어를 포집하는 쉘을포함하며, 상기 코어는 콜레스테롤 유도체를 포함하는 리퀴드크리스 탈을포함한다.
<20> 일측면에서, 본 발명에 따른 리퀴드크리스탈 캡슐의 제조방법은, 콜레스테를 유도체를 가열한후 넁각시켜 리퀴드크리스탈을 얻는 단계; 상기 리퀴드크리스탈을 가열한후 쉘 재료, 또는 쉘 재료와유용성분을 함께 첨가한 다음혼합하여 점액성 액체를 얻는 단계; 및 상기 점액성 액체를 마이크로 직경을 갖는 분출구를 통과시 킨 후 냉각시키는 단계를 포함한다. In one aspect, the liquid crystal capsule according to the present invention comprises a core and a shell for capturing the core, wherein the core comprises a liquid crystal containing a cholesterol derivative. In one aspect, the method for producing a liquid crystal capsule according to the present invention comprises the steps of obtaining a liquid crystal by cooling the cholester derivative after heating; Heating the liquid crystal and then adding a shell material, or a shell material and a useful ingredient together and then mixing to obtain a slime liquid; And cooling the slime liquid through a jet having a micro diameter.
<21> 일측면에서, 본 발명에 따른조성물은 코어 및 상기 코어를 포집하는 쉘을 포함하며, 상기 코어는 콜레스테를유도체를 포함하는 리퀴드크리스탈을 포함한다. In one aspect, the composition according to the invention comprises a core and a shell for collecting the core, the core comprising a liquid crystal comprising a cholester derivative.
<22> 일측면에서, 콜레스테롤유도체는 콜레스테릴 할라이드 및 콜레스테릴 에스 터 중 하나 이상을 포함할수 있다. 일 측면에서, 상기 콜레스테릴 할라이드는 콜 레스테릴 클로라이드, 콜레스테릴 브로마이드, 콜레스테릴 아이오도 및 콜레스테릴 나이트레이트로 구성된 군으로부터 선택된 하나 이상일 수 있다. 일측면에서, 상기 콜레스테릴 에스터는, 탄소수 d 에서 c22까지의 불포화 지방산 또는 포화지방산 과콜레스테를의 에스터일 수 있다. 예컨대, 콜레스테릴 노나노에이트, 콜레스테릴 크로톤에이트, 콜레스테릴 클로르포메이트, 콜레스테릴 도체칸에이트, 콜레스테릴 클로르아이소시안에이트, 콜레스테릴 부티레이트, 콜레스테릴 카르레이트, 콜레스 테릴 올레이트, 콜레스테릴 리놀에이트, 콜레스테릴 리놀린에이트, 콜레스테릴 라 울레이트, 콜레스테릴 이류케이트, 콜레스테릴 미리스트레이트, 콜레스테릴 올레일 카본에이트, 콜레스테¾ 햅실카바메이트, 콜레스테릴 데실카본에이트, 콜레스테릴 이소스테아레이트, 콜레스테릴 아이소스테아릴카본에이트 또는 상기 유도체들의 조 합을들 수 있지만, 이에 한정되는 것은 아니다. In one aspect, the cholesterol derivative may comprise one or more of cholesteryl halides and cholesteryl esters. In one aspect, the cholesteryl halide may be at least one selected from the group consisting of cholesteryl chloride, cholesteryl bromide, cholesteryl iodo and cholesteryl nitrate. In one aspect, the cholesteryl ester may be an ester of unsaturated fatty acid or saturated fatty acid percholester having from d to c 22 carbon atoms. For example, cholesteryl nonanoate, cholesteryl crotonate, cholesteryl chlorformate, cholesteryl dodecanecanate, cholesteryl chlorisocyanate, cholesteryl butyrate, cholesteryl carboxylate, choles Teryl oleate, cholesteryl linoleate, cholesteryl linoleate, cholesteryl laurate, cholesteryl hydrate, cholesteryl myrilate, cholesteryl oleyl carbonate, cholester¾ hepsil carbamate Cholesteryl decyl carbonate, cholesteryl isostearate, cholesteryl isostearyl carbonate or a combination of the above derivatives, but is not limited thereto.
<23> 상기 콜레스테를 유도체를 다양한 방식으로 2종 이상 배합함으로써 원하는 특정 색상을 갖는 리퀴드크리스탈을 얻을수 있다. 예컨대, 상기 리퀴드크리스탈은 콜레스테릴 할라이드 및 콜레스테릴 에스터의 조합을포함하며, 상기 리퀴드크리스 탈은 그린, 레드 및 블루 중 하나 이상의 색상을 지닌 것일 수 있다. 일 측면에서ᅳ 상기 콜레스테를 에스터는 액상인 콜레스테를 에스터를 포함할 수 있다. By combining two or more kinds of the above cholester derivatives in various ways, a liquid crystal having a desired specific color can be obtained. For example, the liquid crystal may include a combination of cholesteryl halides and cholesteryl esters, and the liquid crystals may have one or more colors of green, red, and blue. In one aspect, the cholester ester may include cholester ester in a liquid state.
<24> 일 측면에서, 상기 콜레스테릴 할라이드는 콜레스테릴 클로라이드이며, 상기 콜레스테릴 에스터는 콜레스테릴노나에이트 및 콜레스테릴이소스테아레이트인 리퀴 드크리스탈 캡슐일 수 있다. In one aspect, the cholesteryl halide is cholesteryl chloride, and the cholesteryl ester may be a liquid crystal capsule of cholesteryl nonaate and cholesteryl isostearate.
<25> 일 측면에세 상기 콜레스테릴 에스터는 비액상인 콜레스테릴 에스터와 액상 인 콜레스테릴 에스터를 포함하는 것일.수 있다 . In one aspect, the cholesteryl ester may include a non-liquid cholesteryl ester and a liquid cholesteryl ester.
<26> 액상인 콜레스테릴 에스터는 상온에서 액상이기만하면 어떤 콜레스테릴 에 스터라도사용가능하며, 예컨대, 콜레스테릴 을레이트, 콜레스테릴 이소스테아레이
트, 콜레스테릴 을레일카본에이트, 콜테스테릴 이소스테아릴카본에이트 또는 상기 하나 이상의 에스터의 조합을 들수 있다. Liquid cholesteryl esters can be used with any cholesteryl ester as long as they are liquid at room temperature. For example, cholesteryl acrylate and cholesteryl isostearlay. Cholesteryl to rail carbonate, cholesteryl isostearyl carbonate, or a combination of one or more of the above esters.
<27> 비액상인 콜레스테릴 에스터는상온에서 비액상이기만 하면 어떤 콜레스테릴 에스터라도사용가능하며, 예컨대, 콜레스테릴 노나에이트 콜레스테아릴 아을에이 트 , 콜레스테릴 팔미테이트 또는 상기 하나 이상의 에스터의 조합을들수 있다. <28> 콜레스테릴 할라이드의 양은 전체 리퀴드크리스탈중량에 기초하여 5 내지Non-liquid cholesteryl esters may be any cholesteryl ester as long as they are non-liquid at room temperature, such as cholesteryl nonaate cholesteraryl acetate, cholesteryl palmitate or one or more of the above. Or a combination of esters. The amount of cholesteryl halide is 5 to 5 based on the total liquid crystal weight.
70중량 %일 수 있다. 한측면에서, 콜레스테릴 할라이드의 양은 전체 리퀴드크리스 탈증량에 기초하여 20 내지 40중량 %일 수 있다. 한측면에서, 콜레스테릴 할라이 드의 양은 전체 리퀴드크리스탈중량에 기초하여 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60또는 65중량 % 이상일 수 있다. 다른 측면에서, 콜레스테릴 할라이 드의 양은 전체 리퀴드크리스탈중량에 기초하여 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15또는 10중량 % 이하일 수 있다. It may be 70% by weight. In one aspect, the amount of cholesteryl halide can be 20 to 40 weight percent based on total liquidcris descaling. In one aspect, the amount of cholesteryl halide may be at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 or 65% by weight based on the total liquid crystal weight. In another aspect, the amount of cholesteryl halide can be up to 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15 or 10 weight percent based on the total liquid crystal weight.
<29> 콜레스테릴 에스터의 양은 전체 리퀴드크리스탈 중량에 기초하여 25 내지 95 중량 %일 수 있다. 한 측면에서 콜레스테릴 에스터의 양은 전체 리퀴드크리스탈증 량에 기초하여 60 내지 80중량 %일 수 있다. 한축면에서, 콜레스테릴 에스터의 양 은 전체 리퀴드크리스탈증량에 기초하여 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90또는 95중량 % 이상일 수 있다. 다른측면에서, 콜 레스테릴 에스터의 양은 전체 리퀴드크리스탈 중량에 기초하여 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15또는 10중량 % 이하일 수 있다. The amount of cholesteryl ester can be 25 to 95 weight percent based on the total liquid crystal weight. In one aspect the amount of cholesteryl ester can be from 60 to 80% by weight based on the total amount of liquid crystals. In one axis, the amount of cholesteryl ester is 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, based on the total amount of liquid crystals. 90 or 95% by weight or more. In another aspect, the amount of cholesteryl ester can be up to 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15 or 10 weight percent based on the total liquid crystal weight.
<30> 액상인 콜레스테릴 에스터의 양은 비액상인 콜레스테릴 에스터 중량 100중 량부에 기초하여 50내지 300중량부일 수 있다. 한 측면에서'. 액상인 콜레스테릴 에스터의 양은 비액상인 콜레스테릴 에스터 중량 100중량부에 기초하여 70 내지 200중량부일 수 있다. 한측면에서, 액상인 콜레스테릴 에스터의 양은 비액성 콜레 스테릴 에스터 중량 100중량부에 기초하여 50, 60, 70, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 또는 280중량부 이상일 수 있다. 다른 측면에서 , 액상 인 콜레스테릴 에스터의 양은 비액성 콜레스테릴 에스터 중량 100중량부에 기초하 여 260, 240, 220, 200, 180, 160, 140, 120, 100, 80, 60 또는 50증량부 이하일 수 있다. The amount of the liquid cholesteryl ester may be 50 to 300 parts by weight based on 100 parts by weight of the non-liquid cholesteryl ester. On one side ' . The amount of the liquid cholesteryl ester may be 70 to 200 parts by weight based on 100 parts by weight of the non-liquid cholesteryl ester. In one aspect, the amount of liquid cholesteryl ester is 50, 60, 70, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260 based on 100 parts by weight of the non-liquid cholesteryl ester. Or 280 parts by weight or more. In another aspect, the amount of liquid phosphorus cholesteryl ester is increased by 260, 240, 220, 200, 180, 160, 140, 120, 100, 80, 60 or 50 based on 100 parts by weight of the non-liquid cholesteryl ester. Or less.
<31> 일 측면에서, 리퀴드크리스탈의 색상은 그린이며, 콜레스테릴 할라이드 : 비 액상인 콜레스테릴 에스터 : 액상인 콜레스테릴 에스터의 중량비는 25-35 : 55-65 : 45-55일 수 있다. In one aspect, the color of the liquid crystal is green, and the weight ratio of cholesteryl halide: non-liquid cholesteryl ester: liquid cholesteryl ester can be 25-35: 55-65: 45-55. have.
<32> 일 측면에서, 리퀴드크리스탈의 색상은 레드이며, 콜레스테릴 할라이드 : 비
액상인 콜레스테릴 에스터 : 액상인 콜레스테릴 에스터의 중량비는 45-55 : 25-50 : 45— 55일 수 있다. In one aspect, the color of liquid crystal is red, cholesteryl halide : Liquid cholesteryl ester: The weight ratio of liquid cholesteryl ester may be 45-55: 25-50: 45-55.
<33> 일 측면에서, 리퀴드크리스탈의 색상은블루이며, 콜레스테릴 할라이드 : 비 액상인 콜레스테릴 에스터 : 액상인 콜레스테릴 에스터의 중량비는 35-45 : 45-55 : 45— 55일 수 있다. In one aspect, the color of the liquid crystal is blue, the cholesteryl halide : non-liquid cholesteryl ester : the weight ratio of the liquid cholesteryl ester can be 35-45 : 45-55 : 45-55 days have.
<34> 일 측면에서, 상기 콜레스테릴 할라이드는콜레스테릴 클로라이드이고, 상기 비액상인 콜레스테릴 에스터는 콜레스테릴 노나노에이트이며, 상기 액상인 콜레스 테릴 에스터는콜레스테릴 스테아레이트일 수 있다. In one aspect, the cholesteryl halide is cholesteryl chloride, the non-liquid cholesteryl ester is cholesteryl nonanoate, and the liquid cholesteryl ester is cholesteryl stearateyl. Can be.
<35> 본 명세서에서 " 캡슐" 은, 하나 이상의 연속 쉘에 의해 둘러싸여 있는 하나 이상의 고체 또는 액체 코어를 포함하는 구조를 의미한다 . 천연 쉘 재료로는 예를 들어 아라비아고무, 아가, 아가로스, 말토덱스트린, 알긴산 및 그의 염, 예를 들 어 소듐또는 칼슘 알기네이트, 지방 및 지방산, 세틸 알코올, 콜라겐, 키토산, 레 시틴, 젤라틴, 젤란검, 콜라겐, 콘드로이친황산나트륨과 같은 As used herein, "capsule" refers to a structure comprising one or more solid or liquid cores surrounded by one or more continuous shells. Natural shell materials include, for example, gum arabic, agar, agarose, maltodextrin, alginic acid and salts thereof, such as sodium or calcium alginate, fats and fatty acids, cetyl alcohol, collagen, chitosan, lecithin, gelatin, Such as gellan gum, collagen, and chondroitin sulfate
글리코사미노글리칸 (Glycosaminoglycan) , 알부민, 쉘락, 다당류, 예를 들어 전분 또는 텍스트란, 수크로스 및 왁스가 있다. 반합성 쉘 재료로는 특히 화학적 개질 셀를로오스, 더 특별하게는 셀를로오스 에스테르 및 셀를로오스 에테르, 예를 들어 셀를로오스 아세테이트, 에틸 샐를로오스, 하이드록시프로필 셀를로오스, 하이드톡 시프로필 메틸 셀를로오스 및 카르복시메틸 셀를로오스, 그리고 전분 유도체, 더 특별하게는 전분 에테르 및 전분 에스테르가 있다. 합성 쉘 재료로는 예를 들어 폴 리아크릴레이트, 폴리아미드, 폴리비닐 알코올또는폴리비닐피를리돈과 같은 중합 체가 있다. Glycosaminoglycan, albumin, shellac, polysaccharides such as starch or textan, sucrose and wax. Semi-synthetic shell materials include, in particular, chemically modified cellulose, more particularly cellulose esters and cellulose ethers, for example cellulose acetate, ethyl salose, hydroxypropyl cellulose, hydroxypropyl Methyl cellulose and carboxymethyl cellulose, and starch derivatives, more particularly starch ethers and starch esters. Synthetic shell materials include, for example, polymers such as polyacrylate, polyamide, polyvinyl alcohol or polyvinylpyridone.
<36> 일 측면에서, 상기 쉘은 아가, 젤란검, 왁스 또는 그들의 어느조합일 수 있 다. In one aspect, the shell may be agar, gellan gum, wax or any combination thereof.
<37> 일 측면에서, 상기 쉘은 캡술 전체 중량을 기준으로 0.1 내지 30중량 %의 양 으로 존재할수 있다. 일 측면에서, 상기 쉘은 캡슐 전체 중량을 기준으로 0.5내 지 10중량 ¾의 양으로 존재할수 있다. In one aspect, the shell may be present in an amount of 0.1 to 30% by weight based on the total weight of the capsule. In one aspect, the shell may be present in an amount of 0.5 to 10 weight ¾ based on the total weight of the capsule.
<38> 일측면에서, 본 발명에 따른 리퀴드크리스탈 캡슐의 제조방법은, 콜레스테를 유도체를 가열한후 넁각시켜 리퀴드크리스탈을 얻는 단계 ; 상기 리퀴드크리스탈을 가열한후 쉘 재료, 또는 ¾ 재료와유용성분올 함께 첨가한 다음 흔합하여 점액성 액체를 얻는 단계; 및 상기 점액성 액체를 마이크로 직경을 갖는 분출구를 통과시 킨 후 냉각시키는 단계를 포함한다. In one aspect, the method for producing a liquid crystal capsule according to the present invention comprises the steps of obtaining a liquid crystal by cooling the cholester derivatives after heating; Heating the liquid crystal and then adding the shell material, or the ¾ material and the useful component together and then mixing to obtain a slime liquid; And cooling the slime liquid through a jet having a micro diameter.
<39> 일측면에서, 리퀴드크리스탈은콜레스테릴 할라이드를 가열하는 단계; 상기
가열된 콜레스테릴 할라이드에 콜레스테릴 에스터를 첨가하여 용해시키는 단계; 및 상기 용해물을 냉각시키는 단계를 포함하는 방법에 의해 제조될 수 있다. In one aspect, the liquid crystal comprises heating the cholesteryl halide; remind Adding cholesteryl ester to the heated cholesteryl halide to dissolve it; And it may be prepared by a method comprising the step of cooling the lysate.
<40> 다른측면에서 리퀴드크리스탈은 콜레스테릴 할라이드를 가열하는 단계; 상 기 가열된 콜레스테릴 할라이드에 비액상인 콜레스테릴 에스터를 첨가하여 용해시 키는 단계; 상기 용해물에 액상인 콜레스테릴 에스터를 첨가하는 단계; 및 상기 용 해물을 넁각시키는 단계를 포함하는 방법에 의해 제조될 수 있다. In another aspect, the liquid crystal comprises heating the cholesteryl halide; Dissolving and adding non-liquid cholesteryl ester to the heated cholesteryl halide; Adding liquid cholesteryl ester to the melt; And it may be prepared by a method comprising the step of entangling the lysate.
<41> 일 측면에서, 본 발명에 따른 캡슐의 제조방법에 있어서, 상기 점액성 액체 를 마이크로 직경을 갖는 분출구를 통과시킨 후 넁각시키는 단계는 분출구를통과 한 것을 미리 냉각시켜 놓은 물또는오일에 적가시키는 것을 포함할수 있다. <42> 일 측면에서, 상기 적가를통해 얻어진 구형체들을 메쉬를 통해 걸러낼 수 있다. In one aspect, in the method for producing a capsule according to the present invention, the step of passing the mucus liquid through a jet having a micro diameter and then engraving the drop is added dropwise to the water or oil previously cooled. Can include In one aspect, it is possible to filter the spherical bodies obtained through the dropping through the mesh.
<43> 일 측면에서 콜레스테릴 유도체의 가열 온도는 40 내지 80°C일 수 있다. 다 른측면에서 콜레스테릴 유도체의 가열 온도는 80, 75 , 70 , 65, 60, 55 , 50, 또는 45 fc 이하일 수 있다. 다른측면에서 콜레스테릴 유도체의 가열 온도는 40 , 45 , 50, 55 , 60 , 65 , 또는 70 °C 이상일 수 있다. In one aspect, the heating temperature of the cholesteryl derivative may be 40 to 80 ° C. In another aspect, the heating temperature of the cholesteryl derivative may be 80, 75, 70, 65, 60, 55, 50, or 45 fc or less. In another aspect, the heating temperature of the cholesteryl derivative may be at least 40, 45, 50, 55, 60, 65, or 70 ° C.
<44> 일 측면에서 콜레스테릴 유도체의 넁각온도는 5 내지 30°C의 온도일 수 있 다. 일 측면에서 콜레스테릴 유도체의 넁각온도는 상온일 수 있다. In one aspect, the cooling temperature of the cholesteryl derivative may be a temperature of 5 to 30 ° C. In one aspect, the cooling temperature of the cholesteryl derivative may be room temperature.
<45> 예컨대, 콜레스테릴 할라이드를 전체 리퀴드크리스탈 증량에 기초하여 5 에 서 40중량 ¾의 양으로 40 내지 80°C까지의 온도로 가열한후, 콜레스테릴 에스터를 5내지 40중량¾까지 첨가하여 녹인 후, 여기에 콜레스테릴 에스터 중 액상성분인 콜레스테릴 을레이트, 콜레스테릴 이소스테아레이트, 콜레스테릴 For example, the cholesteryl halide is heated to a temperature from 40 to 80 ° C in an amount of 5 to 40 weight ¾ based on the total liquid crystal increase, and then the cholesteryl ester is added to 5 to 40 weight ¾. After adding and melting, cholesteryl acrylate, cholesteryl isostearate, and cholesteryl, which are liquid components of cholesteryl ester
올레일카본에이트, 콜레스테릴 이소스테아릴카본에이트 또는 상기 하나 이상의 에 스터의 조합을 20 내지 40중량 ¾까지를 첨가하여 리퀴드크리스탈을 제조할수 있다. Liquid crystals can be prepared by adding oleylcarbonate, cholesteryl isostearylcarbonate or a combination of one or more of these esters up to 20 to 40 weight ¾.
<46> 일 측면에서 리퀴드크리스탈의 가열 온도는 60 내지 100 °C일 수 있다. 다른 측면에서 리퀴드크리스탈의 가열 온도는 100, 95, 90 , 85, 80, 75 , 70, 또는 65°C 이하일 수 있다. 다른 측면에서 리퀴드크리스탈의 가열 온도는 60, 65, 70, 75 , 80, 85, 90또는 95°C 이상일 수 있다. In one aspect, the heating temperature of the liquid crystal may be 60 to 100 ° C. In another aspect, the heating temperature of the liquid crystal may be 100, 95, 90, 85, 80, 75, 70, or 65 ° C or less. In another aspect, the heating temperature of the liquid crystal may be at least 60, 65, 70, 75, 80, 85, 90 or 95 ° C.
<47> 일 측면에서 리퀴드크리스탈의 냉각온도는 1 내지 30°C의 온도일 수 있다. In one aspect, the cooling temperature of the liquid crystal may be a temperature of 1 to 30 ° C.
일 '측면에서 리퀴드크리스탈의 냉각온도는 5내지 1ST:일 수 있다. Day "cooling temperature of the liquid crystal in terms of 5 to 1ST: may be.
<48> 일 측면에서, 리퀴드크리스탈올 캡슐레이션 하기 위해 아가, 젤란검, 왁스 등의 쉘 재료의 함량을 캡슐 전체 중량을 기준으로 0.5에서 10중량 ¾까지 넣고 교 반후 물 또는 오일에 적가하여 구형의 투명구체를 얻을 수 있다. 또한, 갈락토실
세라마이드, 세라마이드, 레시틴, 토코페놀류, 폴리페놀류와 같은 피부 유용성분 의 함량을 캡슐 전체 증량을 기준으로 0.1에서 10중량 %까지 용해하여 캡슐이 형성 되기 전 첨가하여 해당물질이 함유된 캡슐을 만들 수 있다. In one aspect, the content of the shell material such as agar, gellan gum, wax, etc., in order to encapsulate liquid crystalol, from 0.5 to 10 weight ¾ based on the total weight of the capsule, is added dropwise to water or oil, Transparent spheres can be obtained. Also, galactosyl The content of useful skin ingredients such as ceramides, ceramides, lecithin, tocophenols and polyphenols can be dissolved from 0.1 to 10% by weight based on the total weight of the capsule and added before the capsules are formed to make capsules containing the substance. .
일 측면에서, 상기 코어는유용성분을 더 포함할수 있다. 일 측면에서, 유 용성분은 지용성 유용성분일 수 있다. 예컨대, 세라마이드, 갈락토실 세라마이드와 같은 글리코실 세라마이드, 레티놀, 레티놀 유도체, 레티닐아세테이트, 레티닐팔미 테이트, 토코페를, 토코페릴아세테이트, 토코페릴리놀레이트, 토코페릴니코티네이 트, 에피갈로카테킨갈레이트, 알파리포산, 리놀레익산, 코엔자임 Q— 10, 레즈베라트 를, 히알루론산, 식물 추출 에센셜 오일 및 이들의 유도체 중 어느 하나또는 이들 의 조합을포함할수 있다. 일 측면에서, 상기 유용성분은 갈락토실 세라마이드일 수 있다. In one aspect, the core may further comprise a useful ingredient. In one aspect, the useful ingredient may be a fat-soluble useful ingredient. For example, glycosyl ceramides such as ceramides, galactosyl ceramides, retinol, retinol derivatives, retinyl acetate, retinyl palmitate, tocofe, tocopheryl acetate, tocopheryl linate, tocopheryl nicotinate, epi Gallocatechin gallate, alpha lipoic acid, linoleic acid, coenzyme Q-10, lezberat, hyaluronic acid, plant extract essential oils and derivatives thereof, or combinations thereof. In one aspect, the useful ingredient may be galactosyl ceramide.
상기와 같은 목적을 달성하기 위하여, 본 발명의 일실시예에 따른 글리코 실'세라마이드는하기 화학식 1로 표시되는 글리코실 세라마이드 화합물일 수 있다. In order to achieve the above object, glycosyl ' ceramide according to an embodiment of the present invention may be a glycosyl ceramide compound represented by the following formula (1).
1] One]
<53> 상기 식에서 , In the above formula,
<54> n은 1 내지 4의 정수이고, N is an integer of 1 to 4,
<55> m은 1 내지 4의 정수이고, M is an integer of 1 to 4,
<56> - Rl, R2 및 ¾는 각각 독립적으로 수소 또는서로 같거나다른 R 1, R 2 and ¾ each independently represent hydrogen or the same or different
글리코실기이고, , R2 및 ¾중 하나 이상은글리코실기이며 Is a glycosyl group, at least one of R 2 and ¾ is a glycosyl group
<57> R4및 ¾는 탄소수 1내지 20의 알킬기 또는 알켄기이다. R 4 and ¾ are alkyl or alkenes having 1 to 20 carbon atoms.
<58> <58>
<59> 본 발명의 또 다른 일실시예에 따른 글리코실 세라마이드는 화학식 1-1 또는
화학식 1-2의 글리코실 세라마 0 Glycosyl ceramide according to another embodiment of the present invention may be represented by Formula 1-1 or Glycosyl Ceram 0 of Formula 1-2
' [화학식 1-1] '[Formula 1-1]
[화학식 1-2] [Formula 1-2]
상기와 같은목적을 달성하기 위하여, 본 발명의 일실시예에 따른 글리코 세라마이드는 하기 화학식 2 로 표시되는글리코실 세라마이드 화합물일 수 있 In order to achieve the above object, the glyco ceramide according to an embodiment of the present invention may be a glycosyl ceramide compound represented by the following formula (2)
[화학식 2] [Formula 2]
(상기 식에서, (In the above formula,
M 및 n은 각각 독립적으로 서로 같거나 다른 1내지 3의 정수 중 어느 하나
이고 M and n are each independently the same or different from each other 1 to 3 integers ego
K 및 1은 각각 독립적으로서로 같거나 다른 1 및 2의 정수 증 어느 하나 0 j는 0또는 1 이고, K and 1 are each independently the same or different integer increments of 1 and 2 0 j is 0 or 1,
A는 수소이며, A is hydrogen,
A1 및 A3는 각각독립적으로 서로 같거나다른글리코실 (glycosyl )기이고, R은 탄소수 1 내지 30의 알킬기이다. ) A 1 and A 3 are each independently the same or different glycosyl groups, and R is an alkyl group having 1 to 30 carbon atoms. )
글리코실 세라마이드는 하기 화학식 2-1 또는 하기 화학식 2-2으로 표시되는 것일 수 있다. 이 때, 상기 화학식 1에서 A1및 A3에 해당하는 글리코실기는모두 갈락토스이다. Glycosyl ceramide may be represented by the following formula (2-1) or (2-2). At this time, the glycosyl groups corresponding to A 1 and A 3 in Formula 1 are all galactose.
[화학식 2-1] [Formula 2-1]
[화학식 2-2] [Formula 2-2]
일 측면에서, 글리코실 세라마이드는 하기 화학식 3으로 표시되는 화합물일
수 있다. In one aspect, glycosyl ceramide is a compound represented by the following formula (3) Can be.
<80> <80>
<82> (상기 식메서, (82 above)
<83> n은 1 내지 4의 정수이고, N is an integer of 1 to 4,
<84> Ri , R2 및 R3는 각각독립적으로수소 또는 서로 같거나 다른글리코실기이고Ri, R 2 and R 3 are each independently hydrogen or the same or different glycosyl groups.
<85> ¾ 및 ¾는 탄소수 1 내지 20의 알킬기 또는 알켄기이다. ) ¾ and ¾ are alkyl groups or alkenes having 1 to 20 carbon atoms. )
<86> <86>
<87> 상기 화합물은 하기 화학식 3-1 및 화학식 3-2로 표시되는 것일 수 있다. The compound may be represented by the following Chemical Formulas 3-1 and 3-2.
<88> [화학식 3-1]<88> [Formula 3-1]
<89>
<90> [화학식 3-2] <89> <90> [Formula 3-2]
<92> 상기 글리코실기는 단당류이면 특별히 제한되는 것은 아니나, 갈락토스 , 리 보스, 아라바노스 , 자일로스, 리불로스, 글루코스 , 프룩토스, 만노스 , 글리세르알 데히드, 디히드록시아세톤, 에리스로스, 에리스를로스, 트레오스, 크실를로스, 타 가토스, 사이코스 (알를로스), 소르보스, 람노스, 릭소스, 알로스, 알트로스, 굴로 스, 이도스 및 탈로스로 이루어진 군에서 선택되는 하나 이상일 수 있다. 바람직하 게는 갈락토스, 리보스, 아라비노스, 자일로스, 리불로스, 글루코스 , 프룩토스, 만 노스, 글리세르알데히드, 디히드록시아세톤, 에리스로스 및 에리스를로스일 수 있 고, 더욱 바람직하게는 갈락토스일 수 있다. 상기 갈락토스, 리보스, 아라비노스, 자일로스, 리불로스, 글루코스, 프룩토스, 만노스, 글리세르알테히드, 디히드특시 아세톤, 에리스로스, 에리스롤로스는 각각순서대로 하기의 화학식으로 표현되는 단당류이다. The glycosyl group is not particularly limited as long as it is a monosaccharide, but it is not particularly limited as long as it is a monosaccharide. One selected from the group consisting of lolos, treos, xyllos, tagatose, psychos (allos), sorbos, rhamnos, lyxos, alos, altrose, gulose, idos and talos It may be abnormal. Preferably galactose, ribose, arabinose, xylose, ribulose, glucose, fructose, mannose, glyceraldehyde, dihydroxyacetone, erythrose and erythrose, more preferably galactose Can be. The galactose, ribose, arabinose, xylose, ribulose, glucose, fructose, mannose, glyceraldehyde, dihydric acetone, erythrose, erythrose are monosaccharides represented by the following formulas, respectively, in order.
<93> 또 다른 일실시예에서, 상기 글리코실기는 탄당일 수 있다. 또 다른 일실 시예에서, 상기 글리코실기는 갈락토스일 수 있다. In another embodiment, the glycosyl group may be sugar. In another embodiment, the glycosyl group may be galactose.
<94> 일실시예에서, 상기 글리코실기는 육탄당의 1번 탄소 위치에서 세라마이드와 결합된 것일 수 있다. 육탄당의 1번 탄소 위치는 갈락토스를 예를 들면 다음과 같 다:
In one embodiment, the glycosyl group may be combined with ceramide at the carbon position of hexose. The carbon position of hexose 1 is, for example, galactose:
D-Galactose Lᅳ Galactose 상기 유용성분은 전체 캡슐 증량에 대해 0.001 내지 80중량 %포함할 수 있다. 일 측면에서, 상기 유용성분은 전체 캡슐 중량에 대해 0. 1, 1, 2, 4 , 5, 7, 8 , 9 , 10 , 15 , 20 , 30, 40또는 50중량 % 이상포함할수 있다. 일 측면에서, 상기 유용성분은 전체 캡슐 중량에 대해 70 , 60 , 50, 40 , 30, 20 또는 10중량 % 이하포 함할수 있다, D-Galactose L ᅳ Galactose The useful ingredient may comprise 0.001 to 80% by weight relative to the total capsule weight. In one aspect, the useful ingredient may comprise 0.1, 1, 2, 4, 5, 7, 8, 9, 10, 15, 20, 30, 40 or 50% by weight or more based on the total capsule weight. In one aspect, the useful ingredient may contain up to 70, 60, 50, 40, 30, 20 or 10% by weight relative to the total capsule weight,
일 측면에서, 본 발명에 따른 조성물은 피부 장벽 기능 개선, 피부 탄력 증 진, 손상된 피부 회복, 피부 보습, 피부주름 개선, 피부 노화 예방, 모발상태 개 선, 또는 아토피성 피부 치료 또는 완화의 용도를 갖는 조성물일 수 있다. 일 측면 에서 본 발명에 따른조성물은 피부 외용제일 수 있다. 일 측면에서 본 발명에 따 른조성물은 화장료조성물 또는 약학조성물일 수 있다. 일 측면에서, 상기 약학 조성물은 경피 투여용 조성물일 수 있다. In one aspect, the composition according to the present invention is intended to improve the skin barrier function, improve skin elasticity, repair damaged skin, moisturize skin, improve wrinkles, prevent skin aging, improve hair condition, or treat or alleviate atopic skin It may be a composition having. In one aspect, the composition according to the present invention may be an external preparation for skin. In one aspect, the composition according to the present invention may be a cosmetic composition or a pharmaceutical composition. In one aspect, the pharmaceutical composition may be a composition for transdermal administration.
• 본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제 제 시에 통상적으로 이용되는 것아라면 어느 것이나 이용가능하다. 예컨대, 락토스, 덱스트로스, 수크로스, 솔비를, 만니를, 전분, 아카시아고무, 인산칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 샐롤로스, 폴리비닐피롤리돈, 셀를로 스, 물, 시럽, 메틸 셀를로스, 메틸히드록시벤조에이트, • Any pharmaceutically acceptable carrier included in the pharmaceutical composition of the present invention may be used as long as it is commonly used at the time of presentation. For example, lactose, dextrose, sucrose, solbi, manny, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, Syrup, methyl cellulose, methyl hydroxybenzoate,
프로필히드록시벤조에이트, 활석, 스테아르산마그네슘 및 미네랄오일 등을 포함 하나, 이에 한정되는 것은 아니다. Propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like, but are not limited to these.
본 발명의 약제학적 조성물은상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할수 있다. The pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavor, an emulsifier, a suspending agent, a preservative, and the like, in addition to the above components.
본 발명의 약제학적 조성물은 다양한 방법으로 투여될 수 있으나, 경피 루
여가가장 바람직하다. 특히, 국부적으로 피부에 도포하여 적용된다. The pharmaceutical compositions of the present invention can be administered in a variety of ways, Leisure is most preferred. In particular, it is applied by applying to the skin locally.
<102> 본 발명의 약제학적 조성물의 적합한투여량은 제제화 방법, 투여 방식, 환자의 연령, 체증 성, 질병 증상의 정도, 음식, 투여 시간, 투여 경로, 배설 속 도 및 반웅 감웅성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망 하는 치료에 효과적인 투여량을 용이하게 결정 및 처방할수 있다. 바람직하게는 본 발명의 약제학적 조성물의 1일 투여량은 약 0.001-100 rag/kg이다. Appropriate dosages of the pharmaceutical compositions of the present invention may include factors such as formulation method, mode of administration, age of patient, degree of disease, degree of disease symptom, food, time of administration, route of administration, rate of excretion and response. The skilled practitioner can readily determine and prescribe a dosage that is effective for the desired treatment. Preferably the daily dose of the pharmaceutical composition of the present invention is about 0.001-100 rag / kg.
<103> 본 발명의 약제학적 조성물은본 발명이 속하는 기술분야에서 통상의 지식 을 가진 자가용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및 /또는부형제를 이용하여 제제화 됨으로써 단위 용량 형태로 제조되거나또는 다 용량용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할수 있다. <104> 본 발명의 또 다른 양태에 따르면, 본 발명은 기능성 화장료 조성물을 제 공한다. <103> The pharmaceutical composition of the present invention may be formulated using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by one of ordinary skill in the art. It may be prepared in the form or prepared by incorporation into a multi-dose container. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of extracts, powders, granules, tablets or capsules, and may further include a dispersant or stabilizer. According to another aspect of the present invention, the present invention provides a functional cosmetic composition.
<105> 본 발명의 화장료 조성물에서 유효 성분으로서의 리퀴드크리스탈 캡슐의 함량은 전체 화장료조성물에 대하여 0.0001-80.0중량 %일 수 있다. 바람직하게는 0.0005-40.0중량 %이고, 보다바람직하게는 0.01-20%중량 %이다. 더욱 더 바람직하 게는 0. 1 내지 10증량 %이다. 함량이 너무 낮으면 효과가 미미하며, 너무 높으면 제 형 안정성이 좋지 않다. The content of the liquid crystal capsule as an active ingredient in the cosmetic composition of the present invention may be 0.0001-80.0% by weight based on the total cosmetic composition. Preferably it is 0.0005-40.0 weight%, More preferably, it is 0.01-20% weight%. Even more preferably from 0.1 to 10% by weight. If the content is too low, the effect is insignificant, and if too high, the formulation stability is not good.
<106> 본 발명의 화장품 조성물에 포함되는성분은 유효성분으로서의 리퀴드크 리스탈 캡술 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예 컨대 항산화제, 안정화제, 용해화제 , 비타민, 안료 및 향료와 같은 통상적인 보조 제 , 그리고 담체를 포함한다. Ingredients included in the cosmetic composition of the present invention include components commonly used in cosmetic compositions in addition to liquid crystal capsule as an active ingredient, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings. Conventional adjuvants such as, and carriers.
<107> 본 발명의 화장료조성물은 당업계에서 통상적으로 제조되는 어떠한 제형 으로도 제조될 수 있으며 , 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제—함유클린성, 오일, 분말파운데이션, 유탁액 파 운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되 는 것은 아니다. 보다상세하게는, 유연 화장수, 영양화장수, 영양 크림, 마사지 크림ᅤ 에센스, 아이 크림, 클렌징 크림, 클렌징 포음, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다. The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactants. —Contains, but is not limited to, cleanliness, oils, powder foundations, emulsion foundations, wax foundations, and sprays. More specifically, it may be prepared in the form of a flexible lotion, a nourishing lotion, a nourishing cream, a massage cream and a essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
<108> 본 발명의 제형이 페이스트, 크림 또는: 겔인 경우에는 담체 성분으로서 동 물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀를로오스 유도체, 폴리에틸렌
글리콜, 실리콘, 밴토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다. 본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토 스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더 가 이용될 수 있고, 특히 스프레이인 경우에는추가적으로 클로로풀루오로히드로카 본, 프로판 /부탄또는 디메틸 에테르와 같은 추진체를 포함할수 있다. When the formulation of the present invention is a paste, a cream or a gel, the carrier components include animal oils, vegetable oils, waxes, paraffins, starches, tracants, cellulose derivatives and polyethylene. Glycol, silicon, bentonite, silica, talc or zinc oxide may be used. When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, and in particular, in the case of a spray, additionally chlorofluorohydrocarca. It may include a propellant such as propane / butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용 해화제 또는유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네 이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1 ,3-부 틸글리콜오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜또는 소르비탄의 지 방산에스테르가 있다. When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizer or an emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene. Fatty acid esters of glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄을 또는 프 로필렌 글리콜과 같은 액상의 회석제, 에특실화이소스테아릴 알코올, 폴리옥시에틸 렌 소르비롤 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀를로오스, 알루미늄 메타히드특시드, 벤토나이트, 아가또는 트라칸트 등 이 이용될 수 있다, When the formulation of the present invention is a suspension, the carrier components include water, ethane or liquefied diluents such as propylene glycol, isosylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters; Suspending agents, microcrystalline cellulose, aluminum metahydride, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지 방족 알코올 설페이트, 지방족 알코올 에테르설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인 지방족 알코올, 지방산 글리세리드, 지방산 디에탄을아미드, 식물성 유, 라놀린 유도체 또는 에록실화 글리세롤 지방산 에스테르 등이 이용될 수 있다. When the formulation of the present invention is a surfactant-containing cleansing agent, the aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid as carrier components Amide ether sulfates, alkylamidobetaine aliphatic alcohols, fatty acid glycerides, fatty acid diethanamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
【발명의 실시를 위한 형태】 [Form for implementation of invention]
이하에서는, 실시예를 들어 본 발명을 더 상세히 설명하고자 하나, 이는 발 명의 범위를 제한하고자 하는 것이 아니고 다만 예시를 위한 것인 점을자명하다. 실시예 Hereinafter, the present invention will be described in more detail by way of examples, which are not intended to limit the scope of the present invention, but are for clarity. Example
[실시예 1] 리퀴드크리스탈의 제조 콜레스테릴클로라이드 30g을 플라스크에 넣고 60°C까지 가열하여 녹인 후 여 기에 콜레스테릴노나노에이트 60g과 콜레스테릴이소스테아레이트 50g을 넣어 함께
용해하여 상은까지 얼음을 이용하여 과넁함으로써 그린색의 리퀴드크리스탈 140g을 얻었다. Example 1 Preparation of Liquid Crystal 30 g of cholesteryl chloride was added to a flask and heated to 60 ° C. for melting. Then, 60 g of cholesteryl nonanoate and 50 g of cholesteryl isostearate were added together. It melt | dissolved and was overexcited using ice to phase silver, and 140g of green liquid crystals were obtained.
<i2i> 콜레스테릴클로라이드 50g을 플라스크에 넣고 60°C까지 가열하여 녹인 후 여 기에 콜레스테릴노나노에이트 30g과 콜레스테릴이소스테아레이트 50g을 넣어 함께 용해하여 상온까지 얼음을 이용하여 과냉함으로써 레드색의 리퀴드크리스탈 130g을 얻 다. <i2i> 50 g of cholesteryl chloride is added to the flask and heated to 60 ° C to dissolve. Here, 30 g of cholesteryl nonanoate and 50 g of cholesteryl isostearate are dissolved together and supercooled with ice to room temperature. Obtain 130 g of Red Crystal.
<122> 콜레스테릴클로라이드 40g을 플라스크에 넣고 60°C까지 가열하여 녹인 후 여 기에 콜레스테릴노나노에이 H 50g과 콜레스테릴이소스테아레이트 50g을 넣어 함께 용해하여 상온까지 얼음을 이용하여 과넁하여 블루색의 리퀴드크리스탈 140g을 얻 었다. 40 g of cholesteryl chloride is added to a flask and heated to 60 ° C to dissolve it. Then, 50 g of cholesteryl nonanoei H and 50 g of cholesteryl isostearate are dissolved together. Then, 140 g of blue liquid crystals were obtained.
<123> <123>
<124> [실시예 2] 리취드크리스탈의 캡슐레이션 [Example 2] Encapsulation of Rich Crystal
<125> <125>
<126> 상기 실시예 1에서 제조된 그린색의 리퀴드크리스탈 20g 을 교반기에 넣고 20 g of the green liquid crystal prepared in Example 1 was added to a stirrer.
80°C까지 가열하여 용해시켰다. 여기에 젤란검 ¾을 넣어 서로 잘 섞이게 교반한 후 정제수 70g 을 넣고 교반하여 잘섞어 준 후 호머믹서를 이용하여 200rpm에서 5 분간 교반하여 주었다. 이렇게 얻어진 점액성 액체를 평균크기 5에서 30 마이크론 정도 되는 분출구를 통하여 1CTC로 넁각해 놓은 물을 담은 다른 교반기에 서서히 적가하였다. 이렇게 해서 얻어진 구형들은 30메시 틀망을 통해 걸러내어 리퀴드크 리스탈이 함유된 캡슐을 얻을 수 있었다. 이때 얻어진 캡슬의 크기는 직경이 5에서 10밀리크기이었다. 제조된 리퀴드크리스탈 캡슐은 도 1에 나타나 있다. Heated to 80 ° C to dissolve. Here, the gellan gum ¾ was stirred to mix well, and then 70 g of purified water was added thereto, followed by stirring. The mixture was stirred at 200 rpm for 5 minutes using a homer mixer. The viscous liquid thus obtained was slowly added dropwise to another stirrer containing 1CTC of water, through a spout having an average size of 5 to 30 microns. The spheres thus obtained were filtered through a 30 mesh framework to obtain a capsule containing liquid crystals. The size of the capsule obtained at this time was 5-10 millimeters in diameter. The prepared liquid crystal capsule is shown in FIG. 1.
<127> <127>
<128> [실시예 3] 갈락토실세라마이드의 제조 Example 3 Preparation of Galactosyl Ceramide
<129> <129>
<130> 갈라토스 100g올 원형 3구플라스크에 넣고 질소 가스를 공급하면서 ZnCl <130> ZnCl while supplying nitrogen gas to a 100g all-round flask with Galatos
150g 과 황산 , 그리고 아세톤 1000ml를 놓고 상온에서 4시간반응한후 농축하 여 아세토나이드 (acetonide) 형태의 갈락토실을 얻었다. 다이아세탈갈락토스는 110 g으로 수율 95.8 ¾로 얻을 수 있었다. 다이아세탈갈락토스와세라마이드 3 및 세라 마이드 3B을 결합시키기 위해, 다이아세탈갈락토스 36g (0. 140몰')을무수 메틸렌 클로라이드 1000 ml에 용해 시킨 후 메탄솔포닐클로라이드 30g (0. 154몰)과트리 에틸아민 15 g (0. 154몰)을 가한후 상은에서 1시간교반해 주었다. 반웅액에 각 각세라마이드 3 및 3B 80g (0.140몰)을추가로투입한후 4시간후 물로 추출하여
세척한후분리된 유기층을 감압증류하여 농축하고 여기에 염산수용액 10%를 첨 가하여 다이아세탈기를 제거 하였으며 남아있는 다이아세탈갈락토스와 미반웅의 세 라마이드를 제거하기 위하여 -4°C에서 2시간동안 메탄올 1000 ml에 재결정하였다. 침전물을 여과한후 건조한후 흰색의 갈락토실세라마이드 80 g (수율 76%)을 수득 하였다. 150 g of sulfuric acid and 1000 ml of acetone were added, and the mixture was reacted at room temperature for 4 hours and concentrated to obtain acetonide-type galactosyl. Diacetal galactose was obtained in 110 g yield 95.8 ¾. To combine diacetal galactose with ceramide 3 and ceramide 3B, 36 g (0.140 mol ') of diacetal galactose was dissolved in 1000 ml of anhydrous methylene chloride, followed by 30 g (0.154 mol) of methane sulphonyl chloride and triethyl. 15 g (0.154 moles) of amine were added, followed by stirring for 1 hour at silver. Add 80 g (0.140 mol) of each ceramide 3 and 3B to the reaction solution, and extract with water after 4 hours. After washing, the separated organic layer was concentrated by distillation under reduced pressure, and 10% hydrochloric acid solution was added thereto to remove the diacetal group, and for 2 hours at -4 ° C to remove remaining diacetal galactose and mibanung ceramide. Recrystallized from 1000 ml of methanol. The precipitate was filtered and dried to give 80 g (76% yield) of white galactosyl ceramide.
<131> <131>
<132> [실시예 4] 갈락토실세라마이드가 함유된 리퀴드크리스탈 캡슐의 제조 Example 4 Preparation of Liquid Crystal Capsule Containing Galactosyl Ceramide
<133> <133>
<134> 도 2에 도시된 바와 같이, 상기 실시예 1에서 제조된 그린색의 리퀴드크리스 탈 20g을 교반기에 넣고 80°C까지 가열하여 용해시켰다. 여기에 젤란검 2g을 넣어 서로 잘섞이게 교반한후 정제수 70g과 상기 실시예 3에서 제조된 갈락토실세라 마이드 6g올 넣고 교반하여 잘섞어 준후호머믹서를 이용하여 200rpm에서 5분간 교반하여 주었다. 이렇게 얻어진 점액성 액체를 평균크기 5에서 30마이크론 정도 되는 분출구를통하여 K C로 냉각해 놓은 불이 담긴 다른 교반기에 서서히 적가하 였다. 이렇게 해서 얻어진 구형들은 30메시 틀망을 통해 걸러내어 리퀴드 크리스탈 이 함유된 캡슐을 얻을수 있었다. 이때 얻어진 캡슐의 크기는 직경이 5에서 10밀 리크기이다. 리퀴드크리스탈 캡슐 내의 갈라토실세라마이드의 농도는 약 3중량 %이 었다. 제조된 갈락토실세라마이드가 함유된 리퀴드크리스탈 캡슐은도 3에 나타나 있다. As shown in FIG. 2, 20 g of the green liquid crystal detalized in Example 1 was added to a stirrer and heated to 80 ° C. to dissolve. 2 g of gellan gum was added to the mixture and stirred well. Then, 70 g of purified water and 6 g of galactosyl ceramide prepared in Example 3 were added to the mixture, followed by stirring. The mixture was stirred at 200 rpm for 5 minutes using a homer mixer. The viscous liquid thus obtained was slowly added dropwise to another stirrer containing fire cooled by KC through a spout of average size 5 to 30 microns. The spheres thus obtained were filtered through a 30 mesh network to obtain a capsule containing liquid crystals. The size of the capsule obtained at this time is 5 to 10 mils in diameter. The concentration of galactosyl ceramide in the liquid crystal capsule was about 3% by weight. The prepared liquid crystal capsule containing galactosyl ceramide is shown in FIG. 3.
<135> <135>
<136> [실험예 1 : 손상된 피부 장벽 복원 효과 1] Experimental Example 1: Effect of Restoring Damaged Skin Barrier
<137> <137>
<138> 상기 실시예 4에 의해 제조된 갈락토실 세라마이드 (세라마이드 3)가포함된 리퀴드크리스탈 캡슐의 피부 장벽 복원 효과를 알아보기 위하여 , 하기와 같은 실험 을수행하였다. 먼저, 20대의 남성 10명의 양쪽상박부의 수분증발량을 TEWL 장비 (TEWAMETERJM210, Germany)로 측정 한후 (정상피부 약 10±2g/hm2) , 어느 한 쪽상박부에 스카치 테이프를 붙였다 떼어 붙이는 것을 20회 반복하면서 수분증발 량이 40-50g./hm2정도에 이를 때까지 반복하였다. 그 다음상기 실시예 4의 리퀴드크 리스탈 캡슐을손상 직 후, 6시간후, 12시간후 및 24시간후에 20ul를 도포하고, 다른 상박부에는 아무것도 도포하지 않은 대조구로 하였다. 48시간후 Biopsy Punch(STIEFEL, 10隱)를 이용하여 피부를 적출 후 면역염 '색 ( immunostaining)을 통 해 조직 검사를 하였다. 그 결과는 도 4에 나타내었다. 도 4 (a)는 표피층에 지질
층이 소실된 피부를, 도 4 (b)는 대조군을, 도 4 (c)는 리퀴드크리스탈캡슐을 처 치한후사진을 나타낸다. 도 4에 나타난 바와 같이, 갈락토실 세라마이드가포함 된 리퀴드크리스탈을 처리하지 아니한 대조군에 비해 갈락토실 세라마이드가 포함 된 리퀴드크리스탈을 처리한 조직 표본에서 표피층의 장벽보호 기능을블 수 있다.In order to determine the skin barrier restoration effect of the liquid crystal capsule containing galactosyl ceramide (ceramide 3) prepared in Example 4, the following experiment was performed. First, measure the water evaporation of both upper and lower heads of 10 males in their 20s (TEWAMETERJM210, Germany) (normal skin approximately 10 ± 2g / hm 2 ), and then attach the scotch tape to one of the upper arm 20 times. The water evaporation was repeated until it reached 40-50 g./hm 2 . Then, the liquid crystal capsule of Example 4 was applied immediately after damage, 6 hours later, 12 hours later, and 24 hours later, 20 ul was applied, and the other upper portion was a control without any application. After 48 hours, the skin was extracted using Biopsy Punch (STIEFEL, 10 隱) and histologically examined through immunostaining. The results are shown in FIG. Figure 4 (a) lipids in the epidermal layer The layer is missing skin, Figure 4 (b) is a control, Figure 4 (c) shows a photograph after treatment with liquid crystal capsules. As shown in Figure 4, it is possible to enable the barrier protection function of the epidermal layer in the tissue samples treated with liquid crystals containing galactosyl ceramides compared to the control without the liquid crystals containing galactosyl ceramides.
<139> " <139>"
<140> [실험예 2:손상된 피부 장벽 복원 효과 2] Experimental Example 2: Effect of Restoring Damaged Skin Barrier 2
<141> <141>
<142> 상기 실험예 1과동일하게 20대의 남성 10명의 양쪽상박부의 수분증발량을 In the same manner as in Experiment 1, the water evaporation amount of both upper and lower heads of 10 males in their 20s was measured.
TEWL장비 (TEWAMETER JM210 , Germany)로 측정 한후 (정상피부 약 10 ± 2g/hm2) , 어느 한쪽 상박부에 스카치 테이프를붙였다 떼어 붙이는 것을 20회 반복하면서 수분중 발량이 40-50g/hm2정도에 이를 때까지 반복하였다. 그 다음 실시예 4의 리퀴드크리 스탈 캡슐을손상 직 후, 45분 후, 6시간후, 12시간후 및 24시간후에 20ul도포 하고, 다론 상박부에는 아무것도도포하지 않은 대조구로 하였다. 시간 경과에 따 라각각손상 직 후, 6시간, 12시간 및 24시간후에 수분증발량을 측정하였다. 그 결과는 손상 전의 정상 TEWL에 대한 대상피부의 TEWL의 회복를로서 손상 직후의 TEWL 회복률을 0%로 하고 손상 전의 정상 TEWL을 100%로 하였을 때의 상대적인 값 으로 나타내었다. 그 결과는 도 5에 나타나 있다. 도 5에 나타난 바와 같이 , 갈락 토실 세라마이드가 포함된 리퀴드크리스탈 캡슬을 처리하면 피부 장벽 복원 효과가 높음을 알수 있다. After measuring with TEWLAMETER (TEWAMETER JM210, Germany) (normal skin about 10 ± 2g / hm 2 ), attaching and detaching Scotch tape on one upper lip 20 times, and the amount of moisture in water is 40-50g / hm 2 Repeat until this time. Next, the liquid crystal capsules of Example 4 were coated with 20ul immediately after the damage, 45 minutes later, 6 hours later, 12 hours later, and 24 hours later. As the time elapsed, the water evaporation was measured 6 hours, 12 hours and 24 hours immediately after each damage. The result is the recovery of the TEWL of the subject skin from the normal TEWL before the injury, and is expressed as a relative value when the TEWL recovery rate after the injury is 0% and the normal TEWL before the injury is 100%. The results are shown in FIG. As shown in Figure 5, it can be seen that the treatment of the liquid crystal capsule containing galactosyl ceramide has a high skin barrier restoration effect.
<143> <143>
<144> 통상적인 방법에 따라하기와 같은조성비로 본 갈락토실 세라마이드가포함 된 리퀴드크리스탈캡슐 및 포함하는조성물을 제조하였으나, 본 발명은 하기의 제 형예에만 한정되는 것은 아니다. The liquid crystal capsule containing galactosyl ceramide and the composition containing the same were prepared according to a conventional method in the following composition ratio, but the present invention is not limited only to the following examples.
<145> <145>
<146> 제형예 1 : 유연 화장수 (스킨) Formulation Example 1 Flexible Lotion (Skin)
<147> <147>
<148> 【표 1】
성분 함량 (중량 ¾) 실시예 4의 갈락토실 세라마이드가 포함된 3.0 리뛰드크리스탈 캡습 <148> [Table 1] Component Content (Weight ¾) 3.0 Ritude Crystal Caps with Galactosyl Ceramide of Example 4
1.3—부팀례 금리콜 5.2 음레임 암코올 1.5 에탄음 3.2 폼리소르베이트 20 3.2 벤조페논 -9 2.0 카르복실비님 증합체 1. 0 글리세린 3.5 향료 미 : 1,3 parts timrye Friday recalled 5.2 um frame cancer ethane alcohol 1.5 3.2 pomri Well polysorbate 20 3.2 2.0 -9 benzophenone carboxylic Sylvie's certificate copolymer 1.0 Glycerin 3.5 Perfume US:
잔량 계 100 Balance meter 100
<149> 제형예 2: 밀크 로션 Formulation Example 2: Milk Lotion
<150> IS. 2] <150> IS. 2]
<151> 제형예 3: 영양 크림 Formulation Example 3: Nutrition Cream
<152> 【표 3】 <152> [Table 3]
<153> 제형예 4: 외용 연고 처방
실시예 4의 갈락토실 세라마이드가포함된 리퀴드크리스탈과유성분을 가 열용해 후 유화제, 방부제 등을 가하고 70°C로 조정하였다. 이것을 호모믹서로 균 질하게 흔합한 다음, 탈기포, 여과, 넁각시켰다. Formulation Example 4: External Use Ointment Prescription After dissolving the liquid crystal fruit oil component containing galactosyl ceramide of Example 4 was added to the emulsifier, preservatives and adjusted to 70 ° C. This was homogeneously mixed with a homomixer and then degassed, filtered and engraved.
【표 4】 Table 4
기능 성부 함량 (%) 주성분 실시예 4의 갈락토실 세라마이드가 포함된 리퀴드 1.0 Functional Content Content (%) Liquid 1.0 containing galactosyl ceramides of active ingredient example 4
크리스탈 crystal
유성분 페트롤라통 잔량 Level of oil petrolatum
세토스테아¾암코읒 2.0 Seto stea ¾ ammonium 2.0
라놀린 3.0 Lanolin 3.0
스쿠알 3.0 Squal 3.0
유화제 세테아레쓰 -20 3.0 Emulsifier Seteareth -20 3.0
방부제 프로필파라벤 적당량 Preservative Propyl Paraben
메칠파라벤 적당량
Methyl paraben
Claims
【청구항 1】 【Claim 1】
코어 및 상기 코어를포집하는 쉘을포함하며 , It includes a core and a shell encapsulating the core,
상기 코어는 콜레스테롤 유도체를 포함하는 리퀴드크리스탈을 포함하는 리퀴 드크리스탈 캡슐. The core is a liquid crystal capsule containing liquid crystal containing a cholesterol derivative.
【청구항 2】 【Claim 2】
제 1항에 있어서, According to clause 1,
상기 콜레스테를 유도체는 콜레스테릴 할라이드 및 콜레스테릴 에스터 중 하 나 이상을포함하는 리퀴드크리스탈 캡술. The cholesteryl derivative is a liquid crystal capsule containing at least one of cholesteryl halide and cholesteryl ester.
【청구항 3】 【Claim 3】
제 2항에 있어서, In paragraph 2,
상기 콜레스테릴 할라이드는 콜레스테릴 클로라이드, 콜레스테릴 The cholesteryl halide is cholesteryl chloride, cholesteryl
브로마이드, 콜레스테릴 아이오도 및 콜레스테릴 나이트레이트로 구성된 군으로부 터 선택된 하나 이상인 리퀴드크리스탈 캡슐. Liquid crystal capsules containing at least one selected from the group consisting of bromide, cholesteryl iodo and cholesteryl nitrate.
【청구항 41 【Claim 41
제 2항에 있어서, In paragraph 2,
.. 상기 콜레스테릴 에스터는, 탄소수 d에서 C22까지의 불포화 지방산또는 포화지방산과콜레스테를의 에스터인 리퀴드크리스탈 캡술. .. The cholesteryl ester is Liquid Crystal Capsul, which is an ester of unsaturated fatty acids or saturated fatty acids with carbon atoms from d to C 22 and cholesterin.
【청구항 5】 【Claim 5】
제 2항에 있어서, In paragraph 2,
상기 리뛰드크리스탈은콜레스테릴 할라이드 및 콜레스테릴 에스터를 포함하 며, The Ritud Crystal contains cholesteryl halide and cholesteryl ester,
상기 리퀴드크리스탈은 색상을 나타내는 것인 리퀴드크리스탈 캡술. The liquid crystal is a liquid crystal capsule that represents color.
【 구항 6] [Old port 6]
제 5항에 있어서, In clause 5,
상기 색상은 그린, 레드 및 블루중 하나 이상인 리퀴드크리스탈 캡술. The color is a liquid crystal capsule in one or more of green, red, and blue.
【청구항 7】 【Claim 7】
제 6항에 있어서, In clause 6,
상기 콜레스테릴 에스터는 비액상인 콜레스테릴 에스터와 액상인 콜레스테릴 에스터를 포함하는 것인 리퀴드크리스탈 캡슐. A liquid crystal capsule wherein the cholesteryl ester includes non-liquid cholesteryl ester and liquid cholesteryl ester.
【청구항 8】 【Claim 8】
• 제 7항에 있어서, .
상기 색상은 그린이며, • In clause 7, . The color is green,
콜레스테릴 할라이드 : 비액상인 콜레스테릴 에스터 : 액상인 콜레스테릴 에 스터의 중량비는 25-35 : 55-65 : 45-55인 리퀴드크리스탈 캡슐, Cholesteryl halide: Liquid crystal capsule, where the weight ratio of non-liquid cholesteryl ester: liquid cholesteryl ester is 25-35: 55-65: 45-55.
【청구항 9】 【Claim 9】
제 7항에 있어서, In clause 7,
상기 색상은 레드이며, The color is red,
콜레스테릴 할라이드 : 비액상인 콜레스테릴 에스터 : 액상인 콜레스테릴 에 스터의 증량비는 45-55 : 25-35 : 45-55인 리퀴드크리스탈 캡슐. Cholesteryl halide: Liquid crystal capsule with an increase ratio of non-liquid cholesteryl ester: liquid cholesteryl ester of 45-55: 25-35: 45-55.
【청구항 10] [Claim 10]
제 7항에 있어서, In clause 7,
상기 색상은 블루이며, The color is blue,
콜레스테릴 할라이드 : 비액상인 콜레스테릴 에스터 : 액상인 콜레스테릴 에 스터의 증량비는 35-45 : 45-55 : 45-55 인 리퀴드크리스탈 캡술. Liquid crystal capsules where the increase ratio of cholesteryl halide: non-liquid cholesteryl ester: liquid cholesteryl ester is 35-45: 45-55: 45-55.
【청구항 11】 【Claim 11】
제 7항에 있어서, In clause 7,
상기 콜레스테릴 할라이드는콜레스테릴 클로라이드이고, 상기 비액상인 콜 레스테릴 에스터는 콜레스테릴 노나노에이트이며, 상기 액상인 콜레스테릴 에스터 는콜레스테릴 스테아레이트인 리퀴드크리스탈 캡슐. The cholesteryl halide is cholesteryl chloride, the non-liquid cholesteryl ester is cholesteryl nonanoate, and the liquid cholesteryl ester is cholesteryl stearate.
【청구항 12】 【Claim 12】
제 1항에 있어서' In paragraph 1'
상기 코어는 유용성분을 더 포함하는 리퀴드크리스탈 캡슐. The core is a liquid crystal capsule further containing useful ingredients.
【청구항 13】 【Claim 13】
제 12항에 있어서, In clause 12,
상기 유용성분은 글리코실 세라마이드를포함하는 리퀴드크리스탈 캡슬. The useful ingredient is a liquid crystal capsule containing glycosyl ceramide.
【청구항 14] [Claim 14]
제 13항에 있어서, According to clause 13,
상기 글리코실 세라마이드는 갈락토실 세라마이드인 리퀴드크리스탈 캡슐. Liquid crystal capsule where the glycosyl ceramide is galactosyl ceramide.
【、청구항 15】 【、Claim 15】
제 1항 내지 제 14항 중 어느 한항에 따른 리퀴드크리스탈 캡슐의 제조방법으 로서 , A method for producing a liquid crystal capsule according to any one of claims 1 to 14,
콜레스테를 유도체를 가열한후 넁각시켜 리퀴드크리스탈을 얻는 단계; 상기 리퀴드크리스탈을 가열한후 쉘 재료, 또는 쉘 재료와 유용성분을 함께
첨가한 다음흔합하여 점액성 액체를 얻는 단계; 및 Obtaining a liquid crystal by heating a cholesterol derivative and then cutting it; After heating the liquid crystal, the shell material, or the shell material and useful components together Adding and then mixing to obtain a viscous liquid; and
상기 점액성 액체를 마이크로 크기의 직경을 갖는 분출구를 통과시킨 후 냉 각시키는 단계를포함하는 리퀴드크리스탈의 제조방법. A method of producing a liquid crystal comprising the step of passing the viscous liquid through a jet having a micro-sized diameter and then cooling it.
【청구항 16】 【Claim 16】
제 15항에 있어서, In clause 15,
상기 리퀴드크리스탈을 얻는 단계는 The steps to obtain the liquid crystal are
콜레스테릴 할라이드를 가열하는 단계; heating cholesteryl halide;
상기 가열된 콜레스테릴 할라이드에 콜레스테릴 에스터를 첨가하여 용해시키 는 단계; 및 Adding and dissolving cholesteryl ester to the heated cholesteryl halide; and
상기 용해물을 냉각시키는 단계를 포함하는 리퀴드크리스탈의 제조방법. A method of producing liquid crystal including the step of cooling the melt.
【청구항 17] [Claim 17]
제 16항에 있어서, According to clause 16,
상기 리퀴드크리스탈올 얻는 단계는 The steps for obtaining liquid crystal ol are:
콜레스테릴 할라이드를 가열하는 단계; heating cholesteryl halide;
상기 가열된 콜레스테릴 할라이드에 비액상인 콜레스테릴 에스터를 첨가하여 용해시키는 단계 ; Adding and dissolving non-liquid cholesteryl ester to the heated cholesteryl halide;
상기 용해물에 액상인 콜레스테릴 에스터를 첨가하는 단계; 및 Adding liquid cholesteryl ester to the lysate; and
상기 용해물을 넁각시키는 단계를 포함하는 리퀴드크리스탈의 제조방법. A method of producing liquid crystal comprising the step of kneading the melt.
【청구항 18】 【Claim 18】
제 1항내지 제 14항 중 어느 한항에 따른 리퀴드크리스탈 캡슐을 포함하는 조성물. A composition comprising the liquid crystal capsule according to any one of claims 1 to 14.
【청구항 19】 【Claim 19】
제 18항에 있어서, 상기 조성물은, 피부 장벽 기능 개선, 피부 탄력 증진, 손 상된 피부 회복, 피부 보습, 피부 주름 개선, 피부 노화 예방, 모발상태 개선, 또 는 아토피성 피부 치료또는 완화의 용도를 갖는조성물. The method of claim 18, wherein the composition is used for improving skin barrier function, promoting skin elasticity, recovering damaged skin, moisturizing skin, improving skin wrinkles, preventing skin aging, improving hair condition, or treating or alleviating atopic skin. A composition having.
【청구항 20】 【Claim 20】
제 19항에 있어서, 상기 조성물은 화장료 조성물 또는 약학조성물인 조성물.
The composition according to claim 19, wherein the composition is a cosmetic composition or a pharmaceutical composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0146646 | 2013-11-28 | ||
KR1020130146646A KR101581212B1 (en) | 2013-11-28 | 2013-11-28 | Cholesterol derivatives-based liquid crystal and capsule containing the liquid crystal |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015080319A1 true WO2015080319A1 (en) | 2015-06-04 |
Family
ID=53199249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/010999 WO2015080319A1 (en) | 2013-11-28 | 2013-11-29 | Cholesterol derivative-based liquid crystal and liquid crystal capsules containing same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101581212B1 (en) |
WO (1) | WO2015080319A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102174527B1 (en) * | 2019-04-30 | 2020-11-06 | 코스맥스 주식회사 | Compound and Cosmetic composition comprising the same for blocking the near infrared rays |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000264826A (en) * | 1999-03-16 | 2000-09-26 | Ryuhodo Seiyaku Kk | Liquid crystal composition and skin cosmetic formulated with the same |
WO2002036074A2 (en) * | 2000-11-01 | 2002-05-10 | Presperse Incorporated | Pigmented liquid crystal materials |
US20020192247A1 (en) * | 2001-04-26 | 2002-12-19 | Lyle Theisen | Thermochromic/photochromic cosmetic compositions |
US20100086506A1 (en) * | 2008-10-06 | 2010-04-08 | Chisso Corporation | Cholesteric liquid crystal composition |
WO2013110010A1 (en) * | 2012-01-19 | 2013-07-25 | Carma Laboratories, Inc. | Compositions and methods for incorporation of encapsulated materials in anhydrous materials |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0145846B1 (en) * | 1995-02-20 | 1998-08-17 | 한동근 | Capsule containing liquid crystal of polymer silicone gum and cosmetic composition comprising |
KR101433913B1 (en) | 2011-04-28 | 2014-09-01 | 주식회사 진영바이오 | Glycosyl ceramide compound, and composition comprising the compound |
KR101936685B1 (en) | 2011-11-16 | 2019-01-11 | (주)아모레퍼시픽 | Pseudo glycosyl ceramide compounds, preparation method thereof, and cosmetic composition containing the same |
KR101969814B1 (en) | 2012-02-24 | 2019-04-18 | 주식회사 진영바이오 | Glycosyl ceramide compounds and preparation method thereof |
-
2013
- 2013-11-28 KR KR1020130146646A patent/KR101581212B1/en active IP Right Grant
- 2013-11-29 WO PCT/KR2013/010999 patent/WO2015080319A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000264826A (en) * | 1999-03-16 | 2000-09-26 | Ryuhodo Seiyaku Kk | Liquid crystal composition and skin cosmetic formulated with the same |
WO2002036074A2 (en) * | 2000-11-01 | 2002-05-10 | Presperse Incorporated | Pigmented liquid crystal materials |
US20020192247A1 (en) * | 2001-04-26 | 2002-12-19 | Lyle Theisen | Thermochromic/photochromic cosmetic compositions |
US20100086506A1 (en) * | 2008-10-06 | 2010-04-08 | Chisso Corporation | Cholesteric liquid crystal composition |
WO2013110010A1 (en) * | 2012-01-19 | 2013-07-25 | Carma Laboratories, Inc. | Compositions and methods for incorporation of encapsulated materials in anhydrous materials |
Non-Patent Citations (1)
Title |
---|
PERSONAL CARE REFERENCE GUIDE, April 2009 (2009-04-01), Retrieved from the Internet <URL:http://www.anshulindia.com/pdfs/ISP%20Personal%20Care%20Reference%20Guide.pdf> * |
Also Published As
Publication number | Publication date |
---|---|
KR20150062261A (en) | 2015-06-08 |
KR101581212B1 (en) | 2015-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108368146B (en) | Nicotinamide mononucleotide derivative, salt thereof, process for producing the same, external preparation for skin, cosmetic, and food additive | |
JP6828228B2 (en) | Wrinkle-reducing cosmetic composition containing gipenoside isolated from Jiaogulan | |
JPH03193754A (en) | Lipid compound, its preparation and composition for treating skin and hair | |
CN103222931A (en) | Compositions | |
JP2006306804A (en) | Wrinkle formation inhibitor | |
KR102112736B1 (en) | composition for preventing of hair loss or promoting hair growth | |
TW201431831A (en) | Novel pseudo-ceramide compound and method for preparing the same | |
KR20210157614A (en) | Method for preparing green tea extract using natural deep eutectic solvent and use thereof | |
CN102335216B (en) | Use of extract of Saussurea involucrate (Kar.et Kir) Sch. Blp in preparation of melanin production inhibitor | |
KR101969814B1 (en) | Glycosyl ceramide compounds and preparation method thereof | |
CN115569086A (en) | High-stability hydroxy pinacolone retinoic acid ester composition and application thereof | |
CN102946894A (en) | Method for preparing broussonetia kazinoki extract | |
WO2015080319A1 (en) | Cholesterol derivative-based liquid crystal and liquid crystal capsules containing same | |
US20180078482A1 (en) | Composition containing theasapogenol derivative as active ingredient | |
JP6902329B2 (en) | Inhibitor of sebaceous gland cell activation | |
KR101433913B1 (en) | Glycosyl ceramide compound, and composition comprising the compound | |
KR20190103897A (en) | Composition for whitening comprising fraction of Inula helenium as an active ingredient | |
JP2013053159A (en) | Skin whitening composition that contains (2z, 8z)-matricaria acid methyl ester as active ingredient | |
KR20130109282A (en) | Water soluble caffeine and preparing method thereof | |
JPH0967245A (en) | Bathing agent | |
JP5689247B2 (en) | Ceramide production promoter and moisturizer | |
CN108697143B (en) | Moisturizing compositions comprising 3-O-galloyl-3,3', 5',7-pentahydroxyflavan | |
JP2017128539A (en) | Multilamellar vesicle preparation comprising acyl basic amino acid derivative and physiologically active substance | |
JP2004284990A (en) | Skin cosmetic and oral bleaching ingredient | |
JP6188422B2 (en) | Anti-inflammatory agent, hyaluronidase inhibitor, antiallergic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13898277 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13898277 Country of ref document: EP Kind code of ref document: A1 |